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PREFACE. 
My experimental work during the last 3 years is gathered 
in this thesis to complete my Ph.D study. The work is carried 
out at Roskilde University financed by a University scholarship 
(Kandidat Stipendium) and under supervision of associate 
professor Birgitte Munch-Petersen. 
The task for this thesis has been concentrated on: 
"Studies of the cytosolic thymidine kinase (TKl) in human cells 
and comparison to the recombinantly expressed enzyme@'. 
The experimental work is divided into two different 
approaches to the problem. The first approach was to develop a 
sensitive method (competitive PCR) to quantitate TKl mRNA and 
to compare TKl mRNA to the enzyme activity. A model system of 
normal lymphocytes stimulated to growth was investigated by 
this method together with leukemic cells, chronic lymphatic 
leukemia (CLL) cells. The other approach was to construct an 
expression vector for TKl in E.coli. The recombinant TKl was 
purified and characterized as compared to native TKl purified 
from human lymphocytes. 
The experimental work is presented as well as a review over the 
field of regulation af TKl. Four papers are included, where two 
are original articles and two are conference proceedings from a 
meeting on Purine and Pyrimidine metabolism (Indiana, may 
1994). Paper I and II is carried out together with PhD-student 
Tina Kristensen, though Tina wrote paper I. Paper III and IV 
are my own work, though my superviser Birgitte Munch-Petersen 
has been tightly connected in the process of all the papers. 
Roskilde University, den 12. december 1994 
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ABBREVIATIONS 
ara-T: 2'-arabinosol-thymidine 
ATP: Adenosine triphosphate 
AZT:3 '-azidothymidine 
BSA: Bovine serum albumine 
CTP: Cytidine triphosphate 
CLL: Chronic lymphatic leukemia 
DTT: Dithiothreitol 
FCS: Fetal calf serum 
HIV: Human immunodeficiency virus 
HSV: herpes simplex virus 
IPTG: Isopropyl-B-D-thiogalactopyranoside 
PCR: Polymerase chain reaction 
PHA: Phytohemagglutinin 
PMSF: Phenylmethylsulphonyl fluoride 
TK: Thymidine kinase 
TKl: Cytosolic thymidine kinase 
TK2: Mitochondrial thymidine kinase 
TTP: Thymidine triphosphate 
In the work of developing new drugs against different 
diseases, the easy part is to develop a drug affecting the 
disease. It is much more complicated to find a drug that only 
cure or inhibit the disease without causing sideeffects. 
Nucleoside analogs are used as drugs in the treatment of 
cancer and virus infections. If the nucleoside analogs are 
phosphorylated by nucleoside kinases in the cell, they 
interfere with the DNA synthesis of the cell and is toxic to 
the cell. Therefore it is important to have a specific 
knowledge of the involved enzymes and in which cells they are 
located. Thymidine kinase (TK) is a vital nucleoside kinase 
phosphorylating many of the nucleoside analogs used in therapy. 
If the cancer cell or virus infected cell (target cell) 
carries a nucleoside kinase specific for the nucleoside analog 
and the normal cell is without this enzyme, the nucleoside 
analog works as a specific drug. This is the case in the 
treatment of Herpes Simplex Virus (HSV) infections (Fyfe et al, 
1978; Elion, 1985). HSV is a DNA virus carrying a gene for TK. 
HSV TK can phosphorylate the nucleoside analog acyclic 
guanidine which is not a substrate for TK in normal cells 
(Elion et al, 1977). Therefore this analog is a very good drug 
at HSV infections. 
It is otherwise with the use of the nucleoside analog 3'- 
azidothymidine (AZT) in Human Immunedeficiency Virus (HIV) 
infections. AZT was found to inhibit the infectivity and 
cytopathic effect of HIV in vitro (Mitsuya et al, 1985). AZT 
inhibits the reverse transcriptase of the virus more 
efficiently than the DNA polymerase (Cheng et al, 1987; Ono et 
al, 1989). On the other hand AZT is also a good substrate for 
the human TKl dominating in dividing cells (Eriksson et 
a1,1991). Therefore this analog is affecting both the virus and 
the normal cells and thereby causing sideeffects, such as 
anemia and bone marrow 
1989). 
TK is present as 
depression (Langtry & Campoli-Richards, 
two isoenzymes in mammalian cells, TKl, 
a cytosolic TK strictly regulated with the cell cycle, and TK2, 
a mitochondriel constitutively expressed TK (Lee & Cheng, 
1976a; Munch-Petersen & Tyrsted, 1977). Therefore the TK level 
is high in dividing cells due to TKl and low in quiescent cells 
due to TK2. Anyhow altered TK enzymes is found in cancer cells 
(Munch-Petersen & Tyrsted, 1985; Munch-Petersen & Tyrsted, 
1986; Munch-Petersen, 1988; Munch-Petersen, 1990). A further 
characterization of these isoenzymes would open for developing 
specific nucleoside analogs and could therefore be valuable in 
diagnosis and therapy. Furthermore, TKl is a strictly cell 
cycle regulated enzyme with documented regulation on several 
levels of expression (Coppock & Pardee, 1987; Gudas et al, 
1988; Groudine et al, 1984; Ito & Conrad, 1990). Thereby it is 
also a very good model system to investigate regulation of gene 
expression in general. 
The first part of this thesis is to develop a sensitive 
method to quantitate TKl mRNA (competitive PCR) and to clarify 
the coherence between TKl mRNA and enzyme activity during PHA 
stimulation of human lymphocytes. Chronic lymphatic leukemic 
(CLL) cells was included in this work because CLL cells are 
non-dividing cells and therefore they should have no TKl enzyme 
activity. On the other hand they are leukemic cells and 
generally cancer cells are characterized by a high TKl activity 
level. Furthermore Munch-Petersen and Tysted (1986) found that 
the dominating TK activity isolated from a CLL patient 
displayed an enzyme kinetic pattern similar to that observed 
with TKl. 
In the present work with CLL cells, it was surprisingly 
found that the TK mRNA level was very high without any 
corresponding enzyme activity. These results are presented as 
proceedings (paper I) and published in Leukemia Research (paper 
II). This study was to investigate the expression of TKl both 
on the mRNA and enzyme level in quiescent and dividing normal 
cells and CLL cells. Parallel with this, we wanted to establish 
an expression system enabling us to express recombinant TKl 
enzyme. Thereby it would be possible to examine the relation 
between the gene and the enzyme. Mutations could be created in 
the gene and the effects investigated on the enzyme level. TKl 
is a low expressed enzyme and it is very difficult to achieve 
large amounts of the enzyme by purification from a human source 
(Ellims et al, 1982; Gan et al, 1983; Munch-Petersen et 
a1,1991; Sherley & Kelly, 1988a). Therefore an expression 
system would make it possible to achieve sufficient amounts of 
enzyme to perform protein structure studies e.g. crystalizing 
the enzyme for x-ray studies. 
The work with the expression system is presented in the 
second part of the thesis. An expression system in E.coli for 
direct expression of unmodified human TKl is developed and the 
recombinant TKl is compared with the native TKl purified from 
human lymphocytes. These results are presented as proceedings 
in paper III and in paper IV as a manuscript. 
The recombinant TKl revealed some interesting 
characteristica. The idea was to express the recombinant TKl, 
purify it and examine if the enzyme was identical to the native 
TKl isolated from human lymphocytes. The recombinant TKl was 
very similar to the native enzyme, with respect to specific 
activity, substrate specificity and K,,, values for the two 
substrates, thymidine and ATP. But when investigating for the 
ATP dependend shift of TKl resulting in two apparent forms with 
different molecular weights recently found by Munch-Petersen et 
al (1993), it was showed that recombinant TKl only appear in 
one form, as the high affinity tetramer. The low affinity dimer 
form of the native TKl, observed in the absence of ATP, was not 
seen with recombinant TKl. Further the recombinant TKl were 10 
fold more sensitive towards TTP than the native enzyme. This 
lead us to suggest, that the native enzyme most likely is post- 
translational modificated in some way by procedures not present 
in E.coli. 
In this thesis the general background for the work is 
outlined followed by the aims of the present investigation. The 
methods are presented as flowdiagrams with explaining text. The 
results are presented and discussed followed by the conclusions 
of the work. The four papers are enclosed after the references. 
Thymidine kinase - a salvage pathway enzyme in the DNA 
precursor metabolism: 
Thymidine kinase (ATP: thymidine 5'phosphotransferase E.C. 
2.7.1.21) is a pyrimidine nucleoside salvage pathway enzyme 
represented by two isoenzymes; TKl and TK2, also called the 
cytosolic and the mithochondrial TK, respectively. Both enzymes 
catalyze the first phosphorylation step of thymidine in the 
salvage pathway of TTP synthesis. TKl is the dominating form in 
dividing cells and TK2 is the only form present in non-dividing 
cells, but in low amounts (Munch-Petersen & Tyrsted, 1977; 
Eriksson et al, 1991b). The two isoenzymes have characteristic 
differences in their enzyme kinetic pattern and subunit 
molecular weights (Munch-Petersen, 1984; Munch-Petersen et al, 
1991). TKl is cell-cycle regulated and the enzyme level is low 
or undetectable in quiescent (G,) cells, but increases 
dramatically when the cells enter the S-phase (Coppock & 
Pardee, 1987; Stuart et al, 1985; Bello, 1974; Sherley & Kelly, 
1988b). 
Imbalances of the DNA precursor pool: 
The regulation of the pathways resulting in the DNA 
precursor pool also called the deoxynucleotide triphosphate 
(dNTP) pool are performed by the catalyzing enzymes. Different 
routes lead to the same final product. For instance dTTP is 
formed from two pathways, a de novo and a salvage pathway 
(figure 1). In the de novo pathway dTTP is synthesized from 
inorganic compounds. In the salvage pathway components such as 
thymidine and deoxyuridine are re-used from the breakdown of 
DNA in dying cells or from damaged DNA excised in the DNA 
repair process. The regulating enzyme for the salvage pathway 
of dTTP is TK and even though dTTP can be synthesized by the de 
novo pathway, TK seems to be very important for the cell as 
nearly all living organisms have a TK. 
FIGURE 1: Flowdiagram 
of the de novo and 
the salvage pathway 
of dTTP metabolism. 
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The pools of the four dNTP's fluctuates with the DNA 
synthesis and the cell cycle. dTTP is the most cell cycle 
regulated nucleoside. dTTP is the key regulator of the enzyme 
catalyzing reduction of ribonucleotides to deoxyribonucleotides 
and therefore it is likely that the regulation of dTTP is 
essential for the balance between the four dNTP's (Reichard, 
1987). 
Production of dTMP is the critical step in the regulation 
of dTTP. dTMP is produced either by thymidylate synthetase 
methylation of dUMP or by TK phosphorylation of thymidine. dUMP 
can be produced by TK phosphorylation of deoxyuridine or by 
dCMP deaminase from dCMP. This gives TK a central role in the 
regulation of dNTP's. 
Dysfunction of the regulation of the dNTP pool is known 
to give severe damage of the cell by increased mutation rate. 
Severe immune diseases as a result of deficiency or malfunction 
of adenosine deaminase is well known (Carson & Seegmiller,l976; 
Carson et a1,1977; Giblett et a1,1972). ATP and dATP are 
accumulated as a consequence of disturbances in the breakdown 
of adenosine. dATP downregulates the activity of ribonucleoside 
reductase, responsible for reduction of ribonucleotides to 
deoxyribonucleotides in the de novo pathway. Therefore 
accumulation of ATP and dATP will deplete the cells for the 
four dNTP's. 
Organisms deficient in TK have problems of regulating the 
dNTP pool with the following increased mutation rate. These 
organisms also have increased sensitivity towards W radiation 
(McKenna & Hickey, 1981). W radiation is known to induce 
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dimers of thymine in the DNA and the dimers are cut out and 
repaired. When the dNTP pools are disregulated in TK deficient 
cells, it is likely that the repair functions repair with the 
increased mutation rate, in the same way as DNA polymerase seen 
with adenosine deaminase deficiency. 
Isoforms of TKl in cancer cell: 
It is generally accepted that there is a close corre- 
lation between the TKl activity and the proliferative state of 
the cell (Littlefield,l966; Bello,1974; Kit,1976; Munch- 
Petersen C Tyrsted,l977; Johnson et a1,1982). Cancer cells are 
characterized with a high proliferation and therefore they have 
a high level of TKl activity. On behalf of this, increased 
levels of TK in the cells are used as indication of 
tumoractivity of some cancers e.g. breastcancer (O'Neill et al, 
1992; Robertson et al, 1990; Schwartz, 1992), non-Hodgkin's 
lymphoma (Hallek, 1992) and acute lymphatic leukemia (Russ0 et 
al, 1987). 
In normal human cells two isoenzymes of TK is present, 
TKl and TK2. They differ in molecular weight, substrate 
specificity and specific activity (Lee & Cheng, 1976b; Munch- 
Petersen, 1984; Munch-Petersen et al, 1991). Different 
isoenzymes are found in leukemic cells (Munch-Petersen & 
Tyrsted, 1988). At least three other isoenzymes were 
identified. TKl-one (oncogenic form of TKl) has thymidine 
substrate kinetics and TTP inhibition kinitics similar to TKl 
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from profilerating lymphocytes whereas a lower molecular weight 
and altered ATP kinetics were found. This isoenzyme was found 
in samples from three patients with acute myelocytic leukemia 
and from a patient with chronic lymphatic leukemia. The 
isoenzymes TK3 and TK4 were very different from TKl and TK2 and 
were found in a patient with acute monocytic leukemia and in a 
patient with acute lymphatic leukemia. 
If the appearence of altered TK's in cancer cells is a 
consequence of a halt on a developmental stage of the cancer 
cell or the altered TK induces the cell to a cancer phenotype 
is not yet clarified. 
The fact that many studies of TK has been performed on 
cell lines which in at least one way are abnormal cells, can 
give rise to speculations about whether the findings are a 
picture of a normal TK or an isoform, related to the phenotype 
of the cell line. 
Regulation of TKl expression and enzymatic activity during the 
cell cycle: 
Human TKl is coded by a 13 kb gene on chromosome 17. It 
consist of 7 exons and large areas of introns (Flemington et 
al, 1987). After transcription and splicing, the mRNA is 1421 
basepair (bp) with an open reading frame of 702 bp encoding a 
234 aminoacid protein (Bradshaw & Deininger, 1984)(figure 2). 
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FIGURE 2: In top of the figure the DNA sequence of TKl is 
illustated. The black areas are the seven exons and the white 
areas are introns. Below is the TKl mRNA illustrated. The seven 
exons of the gene are spliced together with a small 
untranslated part in the 5'end and a large untranslated part in 
the 3'end. 
The regulation of TKl is found on many different levels 
of expression which indicate that it is very important for the 
cell to have a highly controlled TK activity. The precise role 
of the stringent regulation of expression of human TKl is not 
yet elucidated but the fact is, that nearly all living 
organisms have a cell cycle regulated TK. 
In the following I will present the different levels of 
regulation found by investigating human cells or human 
minigenes of TK expressed in TK deficient cells. In the 
investigations performed with human cells different kind of 
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cells are used and the results are not in every case similar. 
This is probably caused by the origin of the different cells. 
Cell lines are widely used and it is known that cell lines, 
being immortal, are deficient in some of the regulatory 
mechanisms possessed by normal cells, which are unable to grow 
in culture as immortal cell lines. 
Promotor control 
The transcription of genes is regulated by promotor 
sequences. The promotor for TKl has been identified to be the 
sequence region spanning -456 to +32 bp. There is a TATA-like 
sequence, two inverted CCAAT sequences and GC-rich sequences 
(Flemington et a1,1987). Kim & Lee (1991) have demonstrated 
that the upstream sequence of the TKl promotor, spanning 
between -64 and -133 bp, designed as CCRU (cell cycle 
regulatory unit), is responsible for the G,/S control of the 
transcription initiation. This region contains one distal 
inverted CCAAT sequence and a GC element. Chang & Cheng (1993) 
found by binding experiments of nuclear proteins to this 
sequence that there is a strong binding activity to the CCAAT 
box. This binding activity is constitutively present in a 
variety of tumor cell lines but not in quiescent fibroblasts. 
The fibroblasts developed binding activity after serum 
stimulation whereas the binding activity in tumor cell lines 
were independent of serum stimulation. They conclude that the 
constitutive interaction of a CCAAT binding factor with the 
promotor is consistent with the loss of stringent cell growth 
regulation associated with a tumorigenic phenotype. Pang & Chen 
(1993) found similary results with fibroblasts; the quiescent 
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fibroblasts had no binding activity, but 24 hours after serum 
stimulation a strong binding activity was seen. Chang & Chen 
(1988) have shown that old fibroblast cells have a 8 fold lower 
expression of TKl mRNA 24 hours after serum stimulation as 
compared to young fibroblast cells. Pang & Chen (1993) found 
that old fibroblast cells had a 30 fold lower binding activity 
after serum stimulation as compared with young fibroblast 
cells. Flemmington et al (1987) were right when they 
providently wrote: "These repeats with their inverted CCAAT 
sequences are very likely to be an important element of the 
human TK promotor, since they are present within a broader 
homology region upstream from a number of cell cycle regulated 
genes, it is also possible that they play a role in that 
regulationn. 
Introns 
Some reports concentrates on the role of introns in the 
regulation of TKl expression. Lipson et al (1989) have studied 
expression of human minigenes under control of different 
promotors. They found that the two first introns increased the 
amount of TKl mRNA but had no effect on the S-phase regulation 
of TKl mRNA. In mouse TK gene, nuclear protein binding sites 
were found in intron 2 (Rotheneder et a1,1991). These binding 
sites did not contribute to growth regulation of TK expression 
but were found to positively modulate the activity of the TK 
promotor. Also hamster TK gene expression is stimulated by 
intron sequences (Lewis 1986). Gross et al (1987) reports that 
the expression of chicken TK gene is not dependent on 
transcriptional regulatory elements located within the introns. 
From these results it is not likely that introns do have a 
major role in the regulation of TK expression during the cell 
cycle. 
Transcriptional control 
Coppock and Pardee (1987) investigated TKl mRNA during 
the cell cycle. They studied the mammalian cells BALB/c3T3. 
They found that TKl mRNA increased about 20 fold between G, and 
S-phase, that the rate of run on TKl transcription increased 2- 
4 fold between Go and S-phase and that halflife of TK mRNA was 
about 8-12 hours in S and M-phase and decreased as cells 
entered quiescence. They suggested that the appearence of TKl 
mRNA in the beginning of S-phase is regulated not only by the 
rate of gene transcription but also by decreased rate of TKl 
mRNA degradation. Similar results were found by Stewart et al 
(1987) where the mRNA level increased 10 - 20 fold during the 
S-phase. Sherley & Kelly (1988b) reported that in HeLa cells 
the level of TKl mRNA only increased less than 3 fold between 
G, and S-phase in contrast to a 15 fold raise in TK protein. 
They proposed that post-transcriptionally mechanisms to 
accounted for the fluctuation in TK protein in contrast to 
Coppock & Pardee (1987) where the fluctuation of mRNA was 
explained as a result of changes in transcription rate and TKl 
mRNA stability. 
Translational control 
It is shown that there is a regulation during the cell 
cycle both on translational rates and the rates of protein 
degradation. Ito & Conrad (1990) have investigated expression 
of human TKl cDNA under control of different promotors in TK 
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deficient rat cells. Under control of the human TKl promotor, 
the level of TKl mRNA and enzyme was low and after serum 
stimulation both TKl mRNA and enzyme increased. When they 
inserted a constitutive promotor, the TKl mRNA was high through 
G,-phase but the enzyme and protein levels low until about 10 
hours after serum stimulation. This demonstrated a regulation 
mechanism on the translational level. Similar results were 
found by Kauffman et al (1991) by human minigenes expressed in 
murine TK deficient cell lines. When a growth independent 
promotor was substituted for the natural TKl promotor, TKl mRNA 
was expressed in quiescent cells, without any expression of TKl 
polypeptide. The normal increase in TK enzyme was obserced at 
S-phase after serum-stimulation. Sherley & Kelly (198833) have 
shown that the TKl polypeptide was around 10 fold increased in 
the S-phase while the TKl mRNA at the same time only increased 
about three times. This indicated that the TKl protein was most 
efficiently translated in the S-phase. In the same work they 
also showed that the halflife of the protein in most of the 
cell cycle is about 40 hours but in a discrete interval of the 
early G,-phase the halflife is less that one hour. Kaufmann & 
Kelly (1991) report that the last 40 aminoacids of TKl, encoded 
by exon 7 seems to be necessary for cell cycle regulation of 
protein levels. In experiments with TKl minigenes expressed in 
TK deficient mouse cells they showed that deletion of the 
carboxyl-terminal 40 aminoacids complete abolishes cell cycle 
regulation and stabilizes the protein throughout the cell 
cycle. When the cells were arrested in metaphase by nocodazole 
(an inhibitor of microtubules), immunoblots showed that 90% of 
the TK polypeptide was cleared within an hour corresponding to 
a halflife of about 20 min. 
Post-translational control 
Posttranslational modifications are reported as a 
regulation mechanism for TKl activity. Chang & Huang (1993) 
have demonstrated that TKl becomes phosphorylated and that 
fluctuation of TK activity is related to the extent of 
phosphorylation of seryl residues of the TKl polypeptide. It is 
important to mention that this work is performed with un- 
differentiated HL60 cells were the TKl expression is not 
stringently controlled except for a very moderate activation of 
TK in respons to growth stimulation. In a recent work Chang et 
al (1994) have investigated TKl phosphorylation in 
proliferating and M-phase arrested HeLa cells. They show that 
TKl is hyperphosphorylated during the M-phase and have a 10 
fold lower affinity for thymidine (&=15.5 PM) than in 
poliferating cells (%=1.5 PM). They suggest that TKl is 
phosphorylated by a mitotic kinase(s) and thereby changed to a 
less active TKl to prevent unnecessary synthesis of TTP at the 
time of mitosis. 
A regulation mechanism on the enzymatic level is found by 
Munch-Petersen et al (1993) with pure TKl from human 
lymphocytes. A reversible ATP-dependent transition between two 
forms of TKl with different enzymatic properties is reported. 
The pure substrate-free TKl showed non-hyperbolic thymidine 
substrate kinetics with an K, of 15 PM. Incubation with ATP at 
4'C induced a timedependent transition to an enzyme form with 
hyperbolic kinetics and a K,,, value of 0.7 PM. The shift between 
the two forms is reversible and the maximum velocity for these 
two forms of TKl were identical. These two forms of TKl did 
also differ in molecular weight when eluted from a superose 
column. The substrate-free TKl appeared as a dimer of 50 kDa 
and TKl incubated with ATP appeared as a tetramer of 100 kDa. 
This indicate that the shift between the two forms of TKl with 
different activities is a result of conformational changes of 
the enzyme. 
The results of Chang et al (1994) and Munch-Petersen et 
al (1993) show that there are two forms of TKl, one with a low 
K, (1.5 PM and 0.7 PM, respectively) and one with a high K, 
(15.5 PM and 15 PM, respectively). Chang et al (1994) achieved 
the kinetic results with crude enzyme extracts and suggested 
that mitotic kinases are responsible for the phosphorylation 
and thereby alter the enzyme affinity. Munch-Petersen et al 
(1993) have performed these investigations with pure enzyme and 
showed that the transition between the two forms occurs at 4'C 
and in a pure enzyme preparation and that these two forms also 
have different native molecular weight. Whether these two works 
complement each other or it is just a coincidence of results 
looking similar but owned to different factors, is not known 
yet. However one thing can be stated, the possibility of 
protein kinases associated with the pure lymphocyte TKl is very 
little. Such a kinase must have the samme sub-unit molecular 
weight and co-purified on the affinity column and the carboxy 
methyl sepharose along with the enzyme. Furthermore the ATP 
dependent transition between the two forms of TKl is carried 
out at 4'C and it is implausible that a human enzyme are active 
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at this temperature. It may be that TKl can carry out 
autophosphorylation, but then the reversible transition also 
requires a phosphatase activity, and this is impossible for a 
small enzyme like TKl (24 kDa). 
Recombinant enzymes: 
Recombinant expression of enzymes started as a way to 
achieve large amounts of a specific enzyme. This is now used 
widely in the industry e.g. to produce washpowder with enzymes 
such as proteinases and lipases. In scientific research the 
method is widely used as an approach to investigate the 
relation between the gene sequence and the protein. When an 
enzyme is recombinantly expressed it is possible to create 
specific mutations and study the effects on the enzyme. 
Further, expression of recombinant enzymes is a method to 
achieve sufficient amounts of low expressed enzymes to perform 
structural studies of the protein e.g. NMR (Nuclear Magnetic 
Resonance), mass spectroscopy and crystalizing the protein for 
x-ray studies. 
Expression of recombinant enzymes can be performed in 
bacteria or eucharyotic cells. Expression in bacteria is simple 
and the growth rate is high as compared to eucharyotic cells. 
Bacteria can not perform post-translational modifications such 
as phosphorylation or glycosylation. Simple eucharyotic cells, 
such as yeast can phosphorylate and glycosylate recombinant 
protein but in many cases it is performed at different sites as 
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compared with the native protein. Expression of recombinant 
enzymes in E.coli is therefore a very common choice also due to 
the high yield of recombinant enzyme. 
The delicate problem in expression of proteins is, that 
the expressed protein can be toxic to E.coli. Even though the 
recombinant protein is not toxic, an accumulation of 
recombinant protein inside E.coli do interfere with the 
metabolism of the bacteria, and the bacteria degrades the 
foreign proteins to survive. Therefore it is convenient to use 
an inducible promotor, which is that the promotor only can bind 
the polymerase when it is induced e.g. with an increase in 
temperature or addition of IPTG. The expression bacteria can 
then be transformed and grown without expression of recombinant 
protein and the expression can be induced at a specific 
timepoint. 
Two main strategies are used in expression of recombinant 
enzymes. Either a direct expression of the protein or 
expression of a fusion protein, where the cDNA coding for the 
protein of interest is spliced together with cDNA coding for 
another protein. A proteinase digestion site is created between 
the two cDNA's. In this way the protein of interest can be 
cleaved from the fusion protein. 
Expression of fusion proteins is preferable in many 
cases. The fusion part of the protein is normally a bacterial 
protein and therefore the fusion protein is more likely to be 
accepted in the bacteria. Futhermore the fusion part can be 
used in the purification of the protein. The fusion protein 
can be fixed on an affinity column and by washing the column 
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with a relevant proteinase, the protein of interest will be 
cleaved from the fusion protein and elute in pure form. A 
number of fusion protein expression vectors are now 
commercially available and can be purchased along with a 
purification kit consisting of the relevant affinity column 
matrix and the proteinase. 
Direct expression have the advantage that the protein of 
interest can be expressed from cDNA with exactly the same base 
sequence as the cDNA for the native protein. With fusion 
proteins, it is in many cases necessary to modify the cDNA at 
the junctions between the cDNA for the two proteins to create a 
proper proteinase site. This results in a slightly modified 
protein. Another advantage of direct expression is that the 
protein can be purified directly by the same purification 
technics applied for the native protein. 
The expression of TKl in the present investigation is a 
direct expression. The aim was to produce sufficient amounts of 
protein for structural studies, as the structure is not known 
for TKl even though a computer model is suggested (Folkers et 
a1,1991). Further, it was the purpose to study the gene 
sequence in relation to the protein and the enzyme activity. 
The strategy was to express a enzyme identical to the native 
enzyme. At the time of planning this, there were no reports on 
known phosphorylation or glycosylation in TKl. The first report 
on phosphorylation of TKl was from Chang & Huang (1993). 
Further the purification of the recombinant TKl would not be a 
problem as we rutinely purify TKl in our laboratory. 
24 
The expressionsystem used to express recombinant TKl. 
In the expression system I have chosen, there is a high 
direct expression of enzyme in E.coli (Studier et al, 1990). 
The vector used, pET3a, carry two cloning sites, BamHl and 
Ndel. When the aminoacid coding region of TKl is inserted at 
these two restriction sites, the expressed protein will be 
translated identical to the native protein. pET3a is 
constructed from the high copy plasmid, pBR322 and carry 
therefore an ampicillin resistens gene. The tetracyclin 
resistens gene of pBR322 is destroyed at the construction of 
pET3a. The vector carries a promotor for T7 RNA polymerase and 
a Shine Dalgarno (SD) sequence upstream the insert and a 
transcriptional termination sequence downstream the insert. The 
pET3a vector is shown in figure 3. 
FIGURE 3: The figure shows 
the pET3a vector. The area 
between the BglII and EcoRV 
restriction sites are the 
area altered as compared to 
the original plasmid, 
pBR322. @lO is the T7 RNA 
polymerase promotor and SD 
is the translational signal. 
NdeI and BamI-II are the 
cloning sites and T@ is the 
region for transcriptional 
termination. 
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ori 
The expression bacteria is a K12 strain of E.coli, 
BL21(DE3). In this bacteria the gene for T7 RNA polymerase, 
under control of the IPTG inducible promotor, lacW5, is 
inserted in the chromosomal DNA. BL21(DE3) can be more 
tolerable against toxic gene products by transformation with 
1ysE or 1ysS plasmids. These plasmids carry the gene for T7 
lysozyme, which inhibit the T7 RNA polymerase and ease the 
lysis procedure after harvesting the cells. The difference 
between 1ysE and 1ysS is shown in figure 4. In lysE, the T7 
lysozyme is expressed from the promotor and there is 
accumulated substantial levels of lysozyme causing high 
suppression of the T7 RNA polymerase. In the 1ysS plasmid the 
gene is orientated in the opposite direction from the promotor 
resulting in lower levels of lysozyme and only a limited 
suppression of the T7 ENA polymerase. I found that 
BL21(DE3)lysS was the most suitable strain for expression of 
the TKl-pET3a vector. 
FIGURE 4: The difference between the 1ysE and 1ysS plasmids. 
The 1ysE is the left and the 1ysS is the right. 
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AIMS OF TEE PRESENT INVESTIGATION 
In the development of new nucleoside analogs in treatment 
of cancer and virus infections, it is very important to have a 
detailed knowledge about the nucleoside analog phosphorylating 
enzymes. It is important to know in which cells the 
phosphorylating enzyme is active, the substrate specificity and 
affinity of the enzyme and in what degree the enzyme fluctuate 
with the cell cycle. 
Therefore I wanted to develope a sensitive test for TKl 
mRNA (competitive PCR) and thereby clarify the relation between 
expression of TKl mRNA and TKl activity in normal mitogen 
stimulated lymphocytes and in white blood cells from patients 
with chronic lymphatic leukemia (CLL). 
The structure of the enzyme is important in the 
prediction of new nucleoside analogs. To clarify the protein 
structure large amounts of protein is required and this is 
impossible to achieve from natural sources, as TKl is a low 
expressed enzyme. An expression system would solve this problem 
and further the relation between the gene and the enzyme could 
be investigated by mutagenisis. 
Therefore I wanted to construct an expression system for 
direct expression of unmodified human TKl to produce high 
amounts of TKl for structure studies. To ensure that the 
properties of the rich source of TKl was identical to the 
native TKl, the recombinant TKl was to be characterized and 
compared with the native TKl. Another goal was to evaluate 
eventual differences with concern to the possible regulation 
mechanisms in human cells as compared to E.coli. 
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Flowdiagram of the methods used in paper I and II 
Bloodsamples from 
CLL patients 
1 
+ 
isolation of 
lymphocytes 
harvesting the 
lymphocytes 
Bloodsamples from 
healthy persons 
1 
PRA stimulation of 
lymphocytes 
1 
The following procedures are identical for lymphocytes from CLL 
patients and healthy persons. The only exception was that 
Northern Blot analysis only were performed on material from 
healthy donors due to lack of material from CLL patients. 
lymphocytes 
enzyme extract RNA purification DNA purification 
1 I L 1 
\I Northern Blot I PCR TX activity amplifying 
both with CTP cDNA exonl and 
and ATP as protein exon2 + 
phosphate donor concentration intron 
1 1 
the competitive PCR assay 
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Flowdiagram of the methods used in paper III and IV 
PCR amplifying the aminoacid 
coding region of human TX1 
from pTKl1 
+ 
subcloning the PCR product 
into pBR322 
cutting the insert out 
and ligate into pET3a 
transforming three 
different bacteria 
OL21 ( DE3) lys E 
from a large volume of 
induced culture, the bacteria 
are harvested and lysed 
gelfiltration on G-25 and 
chromatography on 
3'0TMP-sepharose 
+ 
analysis of recombinant TKl 
by SDS-PAGE 
removal of thymidine and 
bacterial TK and 
concentration of TKl 
on CM-sepharose 
division of the enzyme in 
two aliguots: 
one with ATP (+ATP form) and 
one without ATP (-ATP form) 
elution on G-200 sephadex to 
determine the molecular mass 
and 
G-25 
examination of the kinetic properties 
with the substrates thymidine 
and ATP, the inbitor TTP and 
two substrate analogs 
The methods used in this thesis are described in paper II 
and IV. The detailed procedure will not be repeated here, but 
the principle in the procedures will briefly be described 
according to the flowdiagrams. 
Flowdiagram (p 28) of the methods used in paper (I and) II: 
Overexpression of thymidine kinase mRNA without corresponding 
enzymatic activity in patients with chronic lymphatic leukemia. 
Cells 
Bloodsamples from healthy persons were collected in 
Heparin vacuum tubes from six volenteers at the institute. 
Bloodsamples from five untreated CLL patients were collected in 
the same way at Roskilde Hospital. This were in agreement with 
the physician in charge and the patients. 
Lvmnhocvte isolation 
Within few hours after the sampling, the lymphocytes were 
isolated by a Ficoll-Isopaque gradient centrifigation technic 
(Munch-Petersen et al, 1973). The cells were counted and all 
the CLL cells and 20% of the normal lymphocytes were stored as 
pellets at -7O'C. 
PHA stimulation 
Immidiately after the lymphocyte isolation, the remaining 
80% of the normal lymphocytes were suspended in RPM1 medium + 
10% fetal calf serum and stimulated to growth by PHA at 37'C. 
The cell concentration were lo6 cells/ml. Four bottles were 
31 
prepared for each donor and the cells were harvested 2,3,4 and 
7 days after PHA stimulation. By flowcytometry it was shown, 
that after 24 hours about 30% of the cells were in S-phase. 
This is similar to previous observations (Kofoed et al, 1986). 
The harvested cells were counted and stored at -7O'C in the 
same way as the unstimulated lymphocytes. 
Enzvme extracts 
Enzyme extracts were prepared by suspending the cell 
pellet in lysisbuffer and disrupting the cells by sonication. 
The lysate was centrifuged to remove cell debris and the 
supernatant was used for TK activity measurement and total 
protein determination. The protein content was determined by 
Coomassie brilliant blue according to Bradford (1976). 
TK activity assay 
The TK activity were determined as initial velocities of 
the enzyme reaction, phosphorylating thymidine to TMP at 37'C. 
3H-thymidine was used as substrate in the TK activity assay. 
Samples were applied to DEAE filters 5, 10 and 15 min after 
starting the reaction by addition of enzyme. The filters were 
washed by ammoniumformiate to remove unphosphorylated 3H- 
thymidine and the radioactivity determined by scintillation 
counting. 
Both ATP and CTP were used as phosphate donor in the TK 
activity assay. We wanted to distinguish whether the TK 
activity was due to TKl or TK2 using the pronounced differences 
in substrate specificity. Both isoenzymes utilize ATP 
efficiently as phosphate donor, but TK2 can also use CTP 
efficiently, whereas CTP is a poor substrate for TKl (Lee & 
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Cheng, 1976b; Ellims et al, 1981). The maximun activity was 
obtained by ATP as co-substrate. The activity obtained, when 
CTP was used as co-substrate, were calculated as % of the 
maximum activity. 
RNA purification 
The RNA were prepared according to the guanidine 
thiocyanate method (Chomczynski & Sacchi, 1987). By this method 
total RNA is isolated and the RNA is highly protected against 
RNases due to guanidine thiocyanate. Sharp ribosomal RNA bands 
were achieved, when the RNA were analysed by agarose gel 
electrophoresis indicating a high quality of undegraded RNA. 
Northern blot 
The RNA preparations were denatured and electrophoresed 
through a formaldehyde containing agarose gel. The gel were 
transferred to a Hybond N+ membrane as described (Sambrook et 
al, 1989). The probe were human TKl cDNA from plasmid pTKl1 
(Bradshaw & Deininger, 1984) labelled by 32P-CTP. The 
hybridization were performed with high stringency washing and 
the results were detected by x-ray film exposure. 
cDNA prenaration 
RNA was transcribed to cDNA by a reverse transcriptase 
(RT) assay with random oliginucleotides (hexamers), dNTP's and 
reverse transcriptase. The reaction was terminated after 2 
hours at 37“C. In each experiment a parallel assay was 
performed with 3H-TTP instead of TTP to control the efficiency 
of the reverse transcription reaction. The incorporated 3H-TTP 
were messured by applying a sample on a 3MM Whatmann filter, 
the free 3H-TTP was removed by washing the filter, and 
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remaining radioactivity was determined by scintilationcounting. 
Competitive PCR 
The principle in the competitive PCR method is a co- 
amplification of target cDNA concurrently with the correspon- 
ding genomic DNA (Gillian et al, 1990). Thus, the two templates 
compete for the same substrates and primers ensuring equal 
efficiency of amplification. The genomic DNA serves as internal 
standard. In our experiments we have chosen exon 1 and 2 with 
intron 1 from the TKl gene as internal standard and exon 1 and 
2 as the target cDNA fragment. The fragments were amplified 
using a pair of primers identical to those reported by Lipson 
an'd Baserga (198933). The sizes of the resulting fragments are 
138 bp with cDNA as template and 248 bp with genomic DNA as 
template. The internal standard of 248 bp genomic DNA is 
prepared by PCR with DNA as template and using the primers 
mentioned above. The product is quantified by agarose gel elec- 
troforesis together with different known amounts of DNA. The 
unknown amount of cDNA, is estimated from a set of PCR- 
reactions performed on a dilution series with known amounts of 
the genomic DNA. The PCR products are separated by agarose gel 
electroforesis. The amount of cDNA (in grams) in the sample is 
estimated as that amount (in grams) of genomic DNA giving equal 
intensity of the two amplification products. The number of TKl 
cDNA copies is calculated from the amount of cDNA, by division 
with the molecular weight of the 138 bp cDNA fragment (average 
molecular weight/base = 308). The number of copies of TKl cDNA 
is taken as being representative for the number of copies of 
TKl mRNA. 
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In our experiments with competitive PCR, contamination 
have been the main problem. The level of TKl mRNA in quiescent 
cells are very low and in these cDNA samples contaminating 
genomic DNA interfered with the competitive PCR. We used 
genomic DNA as internal standard and therefore it is critical 
if any genomic DNA is present in the RNA samples. Even though 
we did perform DNase treatment of our RNA samples our detection 
limit at 0.006 copy/cell was most likely determined by residual 
DNA contamination. Another explanation of this problem could be 
unspliced RNA in the RNA preperation. Gudas et al (1990) have 
suggested an order for the splicing of TKl mRNA, where the 
intron between exon 1 and exon 2 are the last intron to be 
spliced away in the mRNA splicing. 
These problems with contamination descibed above can be 
described as internal contamination problems. Another general 
problem when performing PCR is external contamination. This is 
contamination with DNA from the laboratory. The primary source 
is amplified DNA from previous PCR reactions. Precausions can 
be taken such as handling amplified PCR with seperate pipettes 
and in a seperate room, but the risk of contamination is 
increased when the same primers have been used for a period in 
the laboratory. 
Despite these problems, we were able to detect levels of 
TKl mRNA that could not be detected by the Nothern Blot 
technic. 
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Flowdiagram (p 29-30) of the methods used in paper (III and) 
IV: Human cytosolic thymidine kinase expressed in B.coli occurs 
solely as the high affinity tetramer form with the low K, 
value. 
TKl-nET3a vector 
The plasmid pTKl1 containing a complete cDNA sequence of 
human TKl was used to create the insert coding for the human 
TKl. pTKl1 was template in a PCR amplification with two primers 
flanking the aminoacid coding region. These two primers had 
restriction sites in the 5'ends, BamHl and Ndel and they were 
corresponding to the cloning sites in the expression vector, 
pET3a. 
It was not possible to cut the amplification product by 
the two restriction enzymes, therefore the amplification 
product was sub-cloned into pBR322. The PCR product was blunt- 
ended by Klenow polymerase and ligated into the blunt-end 
restriction site, EcoRV of pBR322. From this construction the 
insert was cut with BamBl and Ndel and inserted into the pET3a 
vector. This TKl-pET3a vector was sequenced (Sanger et al, 
1977) to ensure no mutation had occurred during the initial 
PCR. 
TK expression 
Three different E.coli expression strains was transformed 
by the TKl vector. A TK deficient strain, KY895, could not be 
transformed by the vector, indicating that the direct 
expression of TKl were toxic to the cell. Therefore the next 
attempt was to transform a strain adjusted to expression of 
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toxic genes (BL21(DE3)lysE), as the transcription of the vector 
was suppressed. After induction, this resulted in a yield of 50 
pg/liter culture. The cells were harvested 24 hours after IPTG 
induction at 25°C. The third attempt was to transform a strain, 
where transcription of the vector only were slightly suppressed 
(BL21(DE3)lysS). The yield of this system were about 1 mg/liter 
culture. This system was used for the expression of recombinant 
TKl. 
Purification of recombinant TKl 
A large scale volume of the culture were induced to 
expression and the cells were harvested. The bacteria were 
lysed by sonication in lysisbuffer and the enzyme extract was 
cleared by centrifugation. Using sonication to lyse the cells 
have the advantage compared to e.g. the freeze/thaw method, 
that the DNA is disrupted as well and the lysed cells have a 
much lower viscosity. 
The enzyme extract was gelfiltrated on G-25 sepharose to 
remove small molecules and chromatographed on a 3'-TMP-affinity 
column (Munch-Petersen et al, 1991). The thymidine eluted 
protein from the affinity column was purified to more that,95% 
homogeneity shown by SDS-PAGE. To remove thymidine and 
bacterial TK, the fractions were chromatographed on CM 
sepharose. In contrast to the recombinant TKl, the bacterial TK 
do not bind the negative CM groups (Okazaki & Kornberg, 1964) 
After the CM sepharose chromatography, the purified 
enzyme was divided in two aliquots and to one of these ATP was 
added to 2.5 mM. These two aliquots were referred to as +ATP 
enzyme and -ATP enzyme, respectively. The reason for preparing 
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a +ATP and -ATP enzyme was related to previous results showing, 
that the lymphocyte TKl have different enzymatic properties 
depending on the presence or absence of ATP (Munch-Petersen et 
al, 1993). All the experiments to characterize the recombinant 
TKl were performed with both the +ATP and -ATP enzyme. 
Determination of the molecular mass 
The molecular mass of the active enzyme and thereby its 
ability to oligomerize were determined by elution on a G-200 
sephadex column. The elution volume was determined for protein 
standards with a molecular mass of 12, 29, 66, 150 and 200 kDa, 
respectively. A straight line was obtained by plotting the 
logarithm to the molecular mass as a function of elution 
volume. Both the +ATP and -ATP recombinant TKl were determined 
and compared to the lymphocyte +ATP and -ATP enzyme. Before the 
+ATP enzyme were eluted from the column, the column was 
equilibrated with 2.5 mM ATP. 
Enzvme kinetics 
The kinetic properties were examined for the substrates, 
thymidine and ATP and for the inhibitor TTP. The substrate 
specifity were investigated for the nucleoside analogs, AZT and 
ara-T. The kinetic properties of the substrates were 
investigated by varying one of the substrates. In this way 
thymidine kinetics were determined by varying thymidine at a 
constant ATP concentration. The TTP inhibition was investigated 
by varying the TTP concentration at a fixed thymidine and ATP 
concentration. The substrate specifity was determined as the 
enzyme activity with the nucleoside analog, compared to the 
enzyme activity with thymidine as the substrate. 
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The substrate kinetic data were plotted in a Hofstee plot 
(v versus v/s) and the EC,,, values and the cooperativity 
determined. The TTP inhibition data were examined in a reverse 
plot (l/v versus TTP) and the ISowas determined. ISo is the 
inhibitor concentration were the enzyme is 50% inhibited. 
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RESULTS AND DISCUSSION. 
TKl mRNA and enzyme activity in PEA stimulated lymphocytes: 
Lymphocytes stimulated to growth by the mitogen PHA is 
used as a model system of quiescent cells entering the cell 
cycle. This system is previous investigated with respect to TK 
activity, DNA synthesis and cell division (Munch-Petersen & 
Tyrsted, 1977; Tyrsted & Munch-Petersen, 1977; Loeb et al, 
1970; Barlow & Ord, 1975). In this study the TKl mRNA, the 
total TK activity and the proportional amounts of TKl and TK2 
is investigated. 
It is generally accepted that the activity of TKl 
increases with the onset of DNA synthesis. Investigation of TKl 
mRNA levels in quiescent and dividing cells show that TKl mRNA 
is virtually absent in Go/G, cells but, increases with the onset 
of DNA synthesis. However, the results differ depending on 
which cell system is used. Sherley & Kelly (1988b) show that 
the increase of TKl mRNA in HeLa cells is too limited to 
account for the high increase in TKl enzyme activity and .' 
suggest that translational regulation mechanisms is involved. 
They measured a 3 fold increase in TKl mRNA and a 15 fold 
increase of TKl protein. Coppock & Pardee (1987) describe a 20 
fold increase of TKl mRNA corresponding to the increase of TKl 
enzyme activity. 
In dividing lymphocytes, the level of TKl mRNA was 
increased about 100 fold when compared to quiescent lymphocytes 
(paper II). The total TK enzyme activity increased 
concomitantly with the increase of TKl mRNA (figure 5). 
FIGURE 5: The TKl mPWA 
and the TK activity 
followed through PHA 
stimulation. The filled 
circles represent the .20 
TK activity of the left -5 
y-axis and the open -8 
cicles represent the P 
TKl mFUJA of the right p .15 
y-axis. 
F 
I I 
50 100 150 
hours with PHA 
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To ensure that the enzyme activity was due to TKl mRNA we 
characterized the TK enzyme with respect to phosphate donor 
specificity. It is shown (Lee & Cheng, 197633; Ellims et al, 
1981) that TKl uses CTP very poorly as phosphate donor compared 
to ATP, whereas TK2 uses CTP as phosphate donor nearly as 
efficient as ATP. 
As shown in paper II, the TK enzyme in quiescent 
lymphocytes were due to TK2. When the total TK activity was 
followed through the PHA stimulation for seven days, the 
capacity to utilize CTP decreased, indicating the increasing 
dominance of TKl with a peak at the fourth day (figure 6). This 
correlates with previous results, where TKl is the dominating 
TK enzyme in dividing cells and TK2 is the dominating in 
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quiescent cells, though at a low level (Munch-Petersen 61 
Tyrsted, 1977; Munch-Petersen, 1984). 
FIGURE 6: The ability to use CTP instead of ATP as phosphate 
donor is illustrated. Samples from six donors have been 
meassured during PHA stimulation (0 - 7 days). 
Six donors during PHA stimulation 
TKl mRNA and enzyme activity in chronic lymphatic leukemia 
cells: 
Chronic lymphatic leukemic (CLL) cells are characterized 
as non dividing cells. CLL is a lymphoproliferative disorder 
with lymphocytosis around 200 - 600 x lo6 white blood cells/ml 
blood as compared to a normal level of 4 - 11 x lo6 cells/ml 
blood. Ellims et al (1981) found in a study of 12 CLL patients, 
using the CTP/ATP ratio to discriminate between the isoenzymes, 
that in 8 patients the dominating enzyme was TK2. The 
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morphological characteristics of these cells were as small 
mature lymphocytes. In the other 4 Cl1 patients TKl seemed to 
be the dominating enzyme and the morphology showed a 
pleomorphic subpopulation resembling prolymphocytes and 
lymphoblasts. They characterized this pattern as indolent and 
aggressive CLL cells. It is reported that the serum level of TK 
is in correlation with the stage of the disease (KZllander et 
a1,1984) and that there is a correlation of serum TK and the 
spontaneous 3H-thymidine incorporation in the non proliferating 
CLL cells (Kallander et a1,1987). Further Munch-Petersen et al 
(1986) found that a TKl isoenzyme was the dominating enzyme in 
a sample from a CLL patient. 
Because of the quiescent stage of CLL cells it was 
expected to find a low TKl mRNA level and a low TK activity 
level, due to the constitutively expressed TK2. However, 
according to the above reports, an increased level of TK enzyme 
in some of the CLL samples may be found. In the samples from 
five CLL patients, it was shown (paper II) that the TK enzyme 
activity was low and at the same level as in quiescent 
lymphocytes. When the TK enzyme was investigated for phosphate 
donor substrate specificity, it was shown that the TK enzyme 
was TK2. Surprisingly, a loo-fold higher level of TKl mRNA as 
compared to the level in quiescent lymphocytes was found. 
Apparently the CLL cells TKl mFNA was not translated into 
active enzyme as the only TK present, was TK2 with an activity 
level similar to that of quiescent cells. It should be noted 
that our samples from CLL patients were taken just after 
diagnosis and before any treatment was initiated. Therefore the 
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samples most likely represent early stages of disease. 
The high level of TKl mRNA without corresponding TK 
enzyme activity could be explained if the TKl mRNA was defect 
in some way, and thereby not translated or translated into a 
defect enzyme without activity. Therefore a group of graduate 
students investigated the TKl mRNA from CLL samples (Laursen et 
al, 1994). There aim was to study possible differences in the 
TKl mRNA as compared to human lymphocytes. However, they did 
not find any differences by investigating the CLL TKl mRNA. 
They used a method where the TKl mRNA is reverse transcribed to 
cDNA and PCR amplificated. The PCR product is denaturated and 
electrophoresed on a polyacrylamid gel. This method, developed 
by Orita et al (1989) is called Single Stranded Conformational 
Polymorphism (SSCP) and should reveal down to single nucleotide 
deletions or substitutions. Anyhow, they discovered the 
interesting detail that it was considerably more difficult to 
PCR amplify the 3'end of the TKl mRNA as compared to the 5'end. 
The reason for this is not yet clarified. It could indicate a 
difference in the 3'end of the TKl mRNA resulting in a 
translational error not detectable by SSCP. On the other hand 
it could indicate that the very high level of TKl mRNA we found 
in CLL by the competitive PCR for some reason is truncated. As 
we performed the competitive PCR by primers flanking exon 1 and 
exon 2 in the 5'end, we only determine an increased level of 
this region and therefore it cannot be excluded that the TKl 
mRNA is truncated. Further investigations have to be made to 
clarify this discrepancy. In figure 7 is shown the areas 
amplified to the SSCP analysis and the areas amplified in the 
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competitive PCR. 
FIGURE 7: The TKl cDNA is illustrated as the thick line. Above 
the cDNA is the area that is PCR amplified by competitive PCR. 
Below the cDNA the three amplification products used in SSCP 
are showed. 
s’ 3’ 
Expression of recombinant TKl: 
In the efforts to create an expression vector for TKl, a 
strategy was followed as previously used for the expression of 
deoxycytidine kinase (Chottiner et a1,1991). The mRNA was 
transcribed to cDNA and PCR amplified with primers including 
restriction-sites in the S'end. In this way the resulting PCR 
product is flanked by two restriction-sites and can by those be 
cloned into the vector. I chose another vector than Chottiner 
et al (1991) but also a vector from the PET vector system 
developed by Studier et al (1990). The reason for this was, 
that the cloning restriction-sites for the primers have to be 
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restriction sites, which are not present in the mRNA sequence. 
It was not possible to cut the PCR fragment into sticky 
ends. The reason for that, may be, that the restriction-sites 
were too close to the end of the PCR product. Therefore the PCR 
product was subcloned into pBR322 by blunt-end ligation. From 
this clone, it was very easy to cut out the insert by the two 
restriction enzymes and clone it into the expression vector 
(figure 8). 
NdeI BamHI 
ACA WAGC , . . , , . . , . , , . , . , . AAC TGA w GTG 
met ser asn stop 
aminoacid coding region 
FIGURE 8: The figure 
illustrates the 
strategy of how the 
aminoacid coding 
region of TKl is 
inserted into the 
pET3a vector. 
ori 
The initial strategy for expression of the enzyme was to 
use a TK minus E.coli strain, KY895 (Igarashi et a1,1967). I 
wanted to transform this strain with a heat inducible T7 RNA 
polymerase plasmid along with the expression vector under 
control of the promotor for T7 RNA polymerase (figure 9). 
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FIGURE 9: The figure shows the unsuccesful strategy to express 
the TKl-pET3a vector in the TK deficient E.coli, KY895. The 
heat inducible plasmid for T7 RNA polymerase is shown to the 
left and the TKl-pET3a vector is shown to the right. 
Obvious the TKl vector was toxic to KY895 as it was not 
possible to achieve any transformants. This in spite of that, 
KY895 was transformed with the TKl vector without the plasmid 
for T7 RNA polymerase. It seemed like the background 
transcription alone was sufficient for the toxic effect. In 
other respects there were no problems with the transforming 
procedure. KY895 was easily transformed with the T7 RNA 
polymerase plasmid. This increased only slightly the doubling 
time of the bacteria growth as normally seen, when a bacterie 
carries a plasmid. 
The next strategy was to transform an expression bacteria 
suitable for expression of toxic genes, BL21(DE3)lysE. This 
strain has T7 RNA polymerase inserted in the chromosomal DNA 
under control of the IPTG induceble UV5 promotor. The 1ysE 
plasmid transcribes a lysozyme gene from the promotor and this 
enzyme inhibit the T7 RNA polymerase. Besides, the lysozyme 
interferes with the cell membrane which make the cells easier 
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to lyse after harvesting. Using BL21(DE3)lysE, TKl was 
expressed with a yield of 50 pg/liter culture which is a poor 
yield even for a directly expressed enzyme. As the aim was to 
achieve high amounts of TKl enzyme to be able to do structure 
studies, this was not sufficient and acceptable. 
The final strategy was to transform BL21(DE3)lysS which 
is very similar to BL21(DE3)lysE. The only difference is, that 
in the 1ysS plasmid the lysozyme gene is orientated reverse to 
the promotor and this results in a lower transcription of 
lysozyme. Therefore the T7 RNA polymerase is inhibited less 
than by the 1ysE plasmid. In this system the yield was about 1 
mg/liter culture. 
The conditions for expression of the enzyme were 25“C and 
harvesting 24 hours after IPTG induction. Initially I expressed 
the system at 37OC. It resulted in a peak of expressed TKl two 
hours after IPTG induction (figure 10). 
FIGURE 10: The TK activity is followed after IPTG induction. 
The filled circles are the TKl-pET3a vector and the open circle 
are the pET3a vector used as control. 
minutes after IPTG induction 
For some reason the TKl enzyme decreased rapidly after 
this peak point. The culture was pulse labelled with 35S- 
methionine and samples collected over time and analysed by SDS- 
PAGE and x-ray film exposure. The results showed that the 
recombinant TKl produced during the pulse were degraded. Most 
likely, this was due to proteinases of the bacteria metabolism. 
Anyhow, it was not convenient to work with a system were the 
point of harvesting was so critical. When inducing large 
volumes of bacteria it is very difficult to harvest the cells 
at a certain timepoint. Furthermore this peakpoint could easily 
be moved either way as a result of the airing intensity of the 
culture. When expression was carried out at 25°C the peak point 
of expression had a duration of several hours even though the 
same picture of decreased TKl enzyme level after the peak was 
observed. 
Another reason for choosing 25OC as expression condition 
was a report of Fetzer & Folkers (1992) describing a fusion 
protein expression of Herpes Simplex Virus TK in KY895. They 
report, that TK form inclusion bodies at 37o'C but not at 25°C. 
Inclusion bodies are aggregated protein that can be produced in 
expression systems. They could not get these inclusive bodies 
into solution. In fact, I did investigate possible TKl 
aggregation after expression at 37'C, and found by SDS-PAGE 
analysis that TKl was soluble both at 37°C and 25°C. This is 
shown in figure 11. If inclusion bodies were formed, the TKl 
band would be seen with the bacteria lysate but not in the 
lysed and centrifuged samples because such inclusion bodies is 
pelletted during centrifugation. 
FIGURE 11: SDS-PAGE of the proteins expressed by TKl-pET3a and 
pET3a in BL21(DE3)lysS. (A) The outer lanes are molecular 
markers (97, 66, 45, 31, 21, 14 kDa). Lane 1 - 4 are lysed 
bacteria 30 min after induction and lane 5 - 8 are lysed 
bacteria 18 hours after induction. Lane 1 and 5 are uninduced 
pET3a, lane 2 and 6 are induced pET3a, lane 3 and 7 are 
uninduced TKl-pET3a and lane 4 and 8 are induced TKl-pET3a. 
(B) The samples on this SDS-PAGE are the same as in A. The only 
difference is that the cells are centrifugated after lysis by 
sonication and the supernatants are applicated the SDS-PAGE. 
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Recombinant TKl as compared with the native TKl: 
Before producing large amounts of recombinant TKl for 
structural studies e.g. mass spectromotry studies and 
crystalizing the enzyme to x-ray studies, it was important to 
ensure that the recombinant TKl was identical to the native 
TKl. This was done by sequencing the vector, by sub-unit 
molecular mass determination of pure TKl enzyme on SDS-PAGE, 
examining the substrate specifities, studying the enzyme 
kinetics and the molecular mass of the active enzyme. 
The sequence of the TKl vector was determined to ensure 
that no mutation had occurred during the initial PCR and it was 
found that the cDNA sequence of TKl vector was identical to the 
published sequence for human TKl (Bradshaw 61 Deininger, 1984). 
The recombinant TKl was purified by the same procedures used 
for the native TKl (Munch-Petersen et a1,1991), but with a few 
procedure modifications. Proteinase inhibitors were added to 
all buffers, since in preliminary experiments it was found that 
the enzyme were very unstable. After gelfiltration on G-25 the 
enzyme extract of recombinant TKl was chromatographed directly 
on a 3'TMP affinity column and the enzyme was eluted in pure 
form by thymidine. To remove thymidine and bacterial TK the 
fractions were chromatographed by CM sepharose. Bacterial TK in 
contrast to human TKl does not bind to the negative groups of 
CM (Okazaki & Kornberg,l964). The CM fractions were used in the 
kinetic experiments. Recombinant TKl was purified to more than 
95% homogeneity as shown by SDS-PAGE (figure 12). The sub-unit 
molecular weight was similar to the lymphocyte TKI. 
FIGURE 12: Coomassie stained 
SDS-PAGE of pure recombinant 
TKl. Lane 1 - 3 are 1 pg, 
0.5 pg and 0.1 fig BSA, 
respectively. Lane 4 - 5 are 
1 and 10 units of TKl. Lane 
6 - 8 are 0.1, 0.5 and 1 1-14 
of standard molecular markers 
(97, 66, 45, 31, 21 and 14 
kDa). 1 unit of TKl represent 
the enzyme activity converting 
1 nmol of thymidine to TMP per 
min. 
By TK enzyme activity assay it was found, that the 
specific activity was similar to that of the native enzyme. 
Also, the substrate specificity towards AZT and ara-T were 
similar to that of the lymphocyte TKl, 40% and 0%, respectively 
as compared to thymidine as substrate (Table 1). This was 
identical with previous investigations with the lymphocyte TKl 
(Munch-Petersen et al, 1991; Eriksson et al, 1991). 
As described in GENERAL BACKGROUND (p 20-21) Munch- 
Petersen et al (1993) found a hithero unknown regulation 
mechanism of lymphocyte TKl. When stored without ATP, the 
enzyme was a dimer with a low affinity for thymidine (K, = 12- 
15 PM) and when stored with ATP, the enzyme was a tetramer with 
a high affinity for thymidine (K,,, = 0.5 - 0.7 PM). Therefore 
the purified recombinant TKl from CM chromatography was divided 
in two, one with ATP and one without ATP. Surprisingly, there 
was no difference between the two forms of recombinant TKl 
(paper IV). The recombinant TKl appeared only in one form, 
whether it has been incubated with or without ATP, This was 
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shown by investigating the enzyme kinetics with thymidine and 
ATP. With both substrates the enzyme kinetics were similar to 
that obtained with lymphocyte TKl incubated with ATP (table 1). 
The thymidine enzyme kinetics is shown in figure 13. 
FIGURE 13: Hofstee plots of the thymidine enzyme kinetics with 
(A) lymphocyte TKl and (B) recombinant TKl. The filled circles 
are the -ATP form of the enzyme and the open circles are the 
+ATP form of the enzyme. 
1 
A 
5 10 15 
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Table 1. Comparison of the properties of lymphocyte TKl and 
recombinant TKl. 
Lymphocyte TKl Recombinant TKl 
Sub-unit molecular 
mass (kDa) 24 26 
Molecular +ATP 175 155 
mass (kDa) -ATP 75 155 
Thymidine Spec.act. 9,500 10,000 
nmol/min/mg 
'AZT +ATP 40% 46% 
as substrate -ATP 38% 
'ara-T +ATP 0% 0% 
as substrate -ATP 0% 
bATP +ATP 14' 31 
K, (PM) -ATP 140. 27 
bThymidine +ATP 0.5-0.7 0.4 
K, (PM) -ATP 12-15 0.4 
"thy. Hill +ATP 1.2 1.5 
coefficient -ATP 0.7 1.4 
dTTP inhib. +ATP g-10* 1.5 
150 (PM) -ATP g-10* 1.5 
'The substrate analogs AZT and ara-T were determined in % of 
the activity with thymidine as substrate. 
bK,,, values for thymidine and ATP were calculated from Hofstee 
plots (v versus v/s). 
'The thymidine Hill coefficient were determined from Hill plots 
(log v/vlnax- v versus log s). 
dI,o for TTP is the inhibitor concentration at 50% inhibition. 
* Munch-Petersen et al (199533) 
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The different thymidine substrate kinetics of the -ATP 
and +ATP forms of the lymphocyte TKl were related to the 
different molecular mass of the two forms. Thus the molecular 
mass of the lymphocyte TKl as determined by elution on Superose 
200 was a dimer (50 kDa) in the absence of ATP and a tetramer 
(100 kDa) in the presence of ATP. This indicates that ATP 
induces a tetramerization of the 24 kDa TKl from human 
lymphocytes (Munch-Petersen et a1,1993). 
FIGURE 14: Elution of standard proteins on G-200 sephadex. 
fraction number 12 ml1 
fraction number 12 ml1 
In the present work we have determined the apparant 
molecular mass of the lymphocyte and recombinant TKl by elution 
on G-200 sephadex (paper IV). The elution of standard proteins 
are shown in figure 14. In absence and presence of ATP the 
apparent molecular mass of the lymphocyte TKl were 75 kDa and 
175 kDa respectively. The recombinant TKl however, exclusively 
appeared with the high molecular mass. The apparent molecular 
mass in absence and presence of ATP were identical and about 
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155 kDa. This indicates that the ability to dissociate from a 
tetramer structure to a dimer structure was lost in the 
recombinant TKl (figure 15). 
FIGURE 15: Elution of (a) lymphocyte TKl and (b) recombinant 
TKl on G-200 sephadex. 
In this work the apparant molecular weights of the 
lymphocyte TKl by elution on G-200 sephadex was higher, than in 
the previous elution experiments with the same enzyme 
preparation on superose 12 (Munch-Petersen et a1.1991; 
Munch-Petersen et a1.1993). This may be due to a non-globular 
shape of the proteins resulting in different filtration on the 
two column matrices. Similarly, the slightly lower molecular 
mass of recombinant TKl (155 kDa) as compared to the lymphocyte 
TKl (175 kDa) may be explained by an altered conformation of 
the tetramer. As the recombinant TKl can not dissociate to a 
dimer, a tighter association of the four sub-units is probable. 
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Uptil now I had only found differences between 
recombinant TKl and lymphocyte TKl because I have included 
examination of enzyme without ATP. No differences has been 
found between the two enzymes as long as ATP was present. 
Finally the recombinant TKl was examined with respect to 
TTP inhibition. The lymphocyte TKl has a I,, value of 9-10 PM 
TTP (Munch-Petersen et al, 1995b). Surprisingly, the 
recombinant TKl had a Iso value of about 1.5 PM TTP. Therefore 
recombinant TKl is about 10 times more sensitive towards TTP 
than lymphocyte TKl. For both enzymes the sensitivity towards 
TTP was not dependend on incubation with or without ATP. Figure 
16 illustrates the TTP kinetics for the recombinant TKl and the 
lymphocyte TKl. 
FIGURE 16: Reverse plots of of the TTP inhibition kinetic of 
recombinant TKl and lymphocyte TKl. The open squares are 
lymphocyte TKl and the filled squares are recombinant TKl, 
t -ATP 
00’ I 1 I 
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The fact that recombinant TKl only appears in one form in 
contrast to lymphocyte TKl, lead us to suggest a model for 
post-translational modifications of lymphocyte TKl (Munch- 
Petersen et al, 1995a)(figure 17): After translation of TKl, 
the protein is post-translational modificated preventing the 
enzyme from immediate formation of a tetramer. The enzyme forms 
a dimer and can change formation to a tetramer after binding of 
ATP. Recombinant TKl is not post-translational modified and 
form therefore a tetramer immediately after translation. 
FIGURE 17: A model of the effect of the proposed post- 
translational mechanism modifying lymphocyte TKl in contrast to 
recombinant TKl. 
Ret-TKl 
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CONCLUSIONS. 
The sensitive test for quantitating TKl mRNA (competitive 
PCR) detects very low amounts of TKl mRNA, down to 0.006 
copies/cell and is many fold more sensitive than Northern blot. 
The expression of TKl mRNA and TK enzyme activity in 
normal lymphocytes stimulated to growth by PHA is low or 
undetectable in quiescent cells and increases around 100 fold 
with the DNA syntesis and cell division. This result is in 
agreement with other results with stimulated serumstarved 
cells. The only difference is that PHA stimulated cells have a 
delayed entry to S-fase after addition of PHA in contrast to 
stimulated serumstarved cells. This delayed entry to S-fase is 
in agreement with, that lymphocytes are true G, cells. 
The expression of TKl mRNA in CLL cells were remarkably 
high, at the same level as in dividing cells. The TK enzyme 
activity was very low, at the level found in quiescent cells. 
When the phosphate donor specifity of the enzyme was 
investigated is was shown that the TK activity in the quiescent 
cells was due to TK2. 
An expression system for direct expression of TKl was 
constructed in E.coli. The yield was about 1 mg/l culture and 
it can be purified to more than 95% homogeneity. 
The recombinant TKl and TKl purified from lymphocytes, 
had similar sub-unit molecular weight (24 - 26 kDa), specific 
activity (about 10 pmol/min/mg), K, for thymidine (0.4 PM), K, 
for ATP (30 PM), substrate specifity towards AZT (40%) and AraT 
(0%) and molecular weight of the active enzyme (about 155 kDa) 
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as a tetramer. 
The recombinant TKl and the lymphocyte TKl were different 
with respect to TTP as inhibitor. The recombinant TKl was about 
10 fold more sensitive towards TTP. 
The effects of removal of ATP on lymphocyte TKl was not 
seen with recombinant TKl. When ATP was removed from lymphocyte 
TKl, the enzyme changes reversibly from a high affinity 
tetramer to a low affinity dimer. Recombinant TKl only appear 
at the high affinity form and only as a tetramer. The missing 
ability of the recombinant TKl to appear as a low affinity 
dimer may be due to the lack of or changed post-translational 
modifications. 
SUMMARY. 
Thymidine kinase (TK) is a key enzyme in the salvage 
pathway of the nucleoside metabolism catalyzing the first 
phosphorylation step in TTP synthesis. Human cytosolic TK (TKl) 
is highly cell cycle regulated. TKl is regulated on many 
different levels of expression and isoforms with altered 
enzymatic properties are found in cancer cells. Investigation 
of these factors offers possibilities to understand the 
molecular background for TKl expression including to clarify 
general regulation patterns. It also gives valuable information 
for constructing new nucleoside analogs for the therapy of 
cancer and virus infections. 
In the first part of the present investigation a 
sensitive test for quantitating TKl mRNA (competitive PCR) is 
developed and the results show that PHA stimulated lymphocytes 
reveal the same pattern concerning expression of TKl mRNA and 
TKl enzyme activity as serum-stimulated cells. This pattern is 
a low level of TKl mRNA and TKl enzyme activity in quiescent 
cells and a high level of TKl mRNA and TKl enzyme in dividing 
cells. In chronic lymphatic leukemic cells, that are non 
dividing cells, the results surprisingly showed that the TKl 
mRNA level was high and at the same level as found in dividing 
lymphocytes. The high level of TKl mRNA is not translated into 
active enzyme as the TK enzyme activity was low as in quiescent 
lymphocytes. These results indicate, that there is a defect in 
the regulation of TKl in chronic lymphatic leukemic cells. To 
investigate this phenomenon more closely I decided by 
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recombinant technics to examine the relation between the TKl 
gene and the TKl protein. 
In the second part of this investigation a direct 
expression system for human TKl in E.coli was developed to 
produce a source of high amounts of TKl, to be able to examine 
the structure of TKl. The resulting recombinant TKl was similar 
to native TKl purified from human lymphocytes with regard to 
sub-unit molecular weight, specific activity, K, for thymidine, 
K, for ATP, substrate specifity towards AZT and ara-T and 
native molecular weight as a tetramer. 
This indicate that the recombinant and native TKl are 
identical but further investigations showed some interesting 
differences. Recombinant TKl is about 10 fold more sensitive 
towards TTP as inhibitor. Furthermore the effect of removal of 
ATP from the native TKl on the enzyme kinetics and native 
molecular weight was not found for recombinant TKl. Native TKl 
shifts reversibly between a low affinity form - a dimer when 
ATP is absent from the enzyme, to a high affinity form - a 
tetramer when ATP is present. Recombinant TKl exclusively 
appear at the high affinity form and only as a tetramer also in 
the absence of ATP. 
This indicate that TKl is post-translationally modified 
in human cells and that this modification can not be performed 
in E.coli. 
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DANISH SUMMARY. 
Thymidin kinase (TK) er et nergle enzym i salvage pathway 
(genbrugsvejen) af nucleosid metabolismen, der katalyserer den 
fnrrste fosforylering i syntese af TTP. Human cytoplasmatisk TK 
(TKl) er et stringent celle cyklus reguleret enzym. TKl bliver 
reguleret pg mange forskellige niveauer under ekspressionen og 
forskellige isoformer er fundet i cancer teller. Undersegelse 
af disse faktorer giver mulighed for at for&& den molekylaere 
baggrund for ekspressionen af TKl foruden at fb generelle 
regulerings msnstre belyst. Det vi1 ogs& give vaerdifulde 
oplysninger i forbindelse med konstruktion af nye nukleosid 
analoger, der bliver brugt til behandling af cancer og virus 
infektioner. 
I farrste de1 af denne undersagelse er en ferlsom test til 
kvantitering af TKl mRNA (competitive PCR) blevet udviklet og 
resultaterne viser at PHA stimulerede lymfocytter udviser det 
samme monster som serum-stimulerede teller med hensyn til 
ekspression af TKl mRNA og TKl enzym. Der er et lavt niveau af 
TKl mRNA og TKl enzym i hvilende teller og et herjt niveau af 
TKl mRNA og TKl enzym i delende teller. I kronisk lymfatisk 
leukemiske teller (CLL teller) viste resultaterne overraskende 
at TKl mRNA niveauet var hrajt, som i delende teller. Det harje 
niveau af TKl mRNA blev ikke translateret til aktivt enzym, 
id& TKl enzym aktivitet var lige s% lavt som i ikke delende 
teller. Dette indikerer, at CLL teller har en defekt i 
reguleringen af TKl. For at unders0ge dette fanomen naermere, 
besluttede jeg ved anvendelse af recombinant teknikker at 
underserge sammenhzngen mellem TKl genet og TKl proteinet. 
I anden de1 af dette arbejde er et direkte ekspressions 
system for human TKl i E.coli blevet udviklet for at f& en 
kilde for store maengder TKl og derved blive i stand til at 
underserge strukturen af TKl proteinet. 
Rekombinant TKl ligner det naturlige TKl (oprenset fra 
humane lymfocytter) med hensyn til sub-unit molekylvegt, 
specifik aktivitet, K, for thymidin, K, for ATP, substrat 
specifitet med AZT og ara-T og molekylvaegt af det aktive enzym, 
som er en tetramer. 
Dette indikerer at enzymerne er identiske, men videre 
understigelser viste nogle interessante forskelle. Rekombinant 
TKl er ca 10 gange mere fnrlsom overfor TTP som haemmer. Der ud 
over findes de effekter, som fjernelse af ATP har pa enzym 
kinetikken og molekylvogten af det naturlige TKl, ikke ved 
rekombinant TKl. Det naturlige TKl skifter reversibelt mellem 
en lav affinitets form - som dimer, n&r ATP er fjernet fra 
enzymet til en hsj affinitets form - som tetramer, n&r ATP er 
til stede. Rekombinant TKl findes kun som h0j'affinitets form 
og kun som tetramer, ogs& selvom ATP er fjernet fra enzyrnet. 
Dette indikerer, at TKl bliver post-translationelt 
modificeret i humane teller og at disse modifications 
mekanismer bliver udfort i E.coli. 
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INTRODUCTION 
Thymidine kinase is an enzyme in the pyrirnidine salvage pathway that, with ATP as 
co-substrate, catalyzes the phosphorylation of deoxythymidine to deoxythymidine 
monophosphate (dTMP) which is subsequently converted to dTT’P and utilized for DNA 
synthesis. 
In mammalian cells there are two thymidine kinases (TK), the constitutively 
expressed TK2, and the S-phase specific TK1 which is only present in dividing cells’. 
Lymphocytes from patients with chronic lymphatic leukemia (CLL) are non-dividing 
and it is therefore plausible that the low TK activity in these cells almost exclusively is 
due to TK2. However, a thymidine kinase with similar enzyme kinetic pattern as that 
observed with TK1 from lymphocytes stimulated to growth by the mitogene 
phytohemagglutinin has been reported*. Since TKl expression is tightly regulated 
thoughout the cell cycle with transcriptional, translational as well as post-translational 
regulatory mechanism3, the occurrence of TK1 in non-dividing CLL cells may be due to 
a change in the control of the cell cycle regulated expression of the TKl gene. 
To investigate the transcriptional expression of TKl mRNA in CLL cells, we have 
measured the level of TKl mRNA with the competitive polymerase chain reaction 
(competitive PCR), and compared this rnRNA level with the TK enzyme activity. Surpri- 
singly, we have found that the ratio of TKl mRNA/TK activity in lymphocytes from CLL 
patients was about 60-400 fold higher than in lymphocytes from healthy persons. 
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METHODS 
Lymphocytes from peripheral blood from 6 healthy persons and from 5 patients with 
untreated CLL were isolated by the Ficoll-Isopaque technique. 
Lymphocytes from healthy persons were stimulated to growth by PHA in RPMI 1640 
medium supplemented with 10% fetal calf serum, 20 pg/ml PHA and 20 pg/rnl 
penicillin/streptomycin at a concentration of lo6 cells pr ml in 5% CO, at 37°C. The 
lymphocytes were divided in portions of 5 x lo6 cells, and in each portion, TK activity was 
determined by the DE-81 paper method as described4 and total protein was determined 
by the Bradford assag. Total RNA was isolated with the guanidine thiocyanate method6, 
transcribed to cDNA and quantitated by the competitive PCR method’. TKl cDNA, 
taken as representative for TKl mRNA, was co-amplified with a dilution series of 
competitor DNA. Exon 1 and 2 with intron from the TKl gene served as competitor 
DNA and exon 1 and 2 of the TKl gene as the cDNA fragment to be quantitated. The 
fragments were amplified using a pair of primers identical to those reported by Lipson 
and Baserga’. The sizes of the resulting fragments was 138 bp with cDNA as template 
and 248 bp with competitor DNA as template. The relative amounts of cDNA versus 
competitor DNA were measured by scanning of ethidium-bromide stained gels. Because 
the starting concentration of the competitor DNA was known, the amount of cDNA (in 
grams) in the sample could be estimated as that amount of competitor DNA where equal 
intensities of the two amplification products were obtained. The number of TKl cDNA 
copies was calculated from the amount of cDNA, by dividing the amount of cDNA with 
the molecular weight of 1 copy of the 138 bp cDNA fragment. 
The amplification was performed in a Perkin-Elmer/Cetus Thermal Cycler according 
to the following program: denaturation for 1 min at 95”C, annealing for 1 min at 60°C 
and polyrnerization for 1 min at 72”C, for 35 cycles. 
RESULTS AND DISCUSSION 
Table 1 shows the ratio of TKl mRNA copies and TK activity in non-dividing 
lymphocytes from 6 healthy persons and in lymphocytes from 5 patients with CLL. As 
seen, the ratio TKl mRNA copies/TK activity in CLL cells is 60 to 400 fold higher than 
in non-dividing lymphocytes. The TK activity in CLL cells is of a magnitude as expected 
for non-dividing cells, while the expression of TKl rnRNA is very high and in the range 
of the TKl rnRNA level in PHA stimulated healthy donor lymphocytes. In these 
experim,ents the TM mRNA level is 3-98 x lo6 copies/mg protein (results are not 
shown). 
The detection limit in the assay is around 6 x lo” copies of TKl mRNA/mg protein 
or 0.006 copies/cell. Below this level, a 248 bp amplification product, interferes with the 
competitive PCR. This is probably a result of traces of DNA or non-spliced RNA in the 
RNA preparation. The results indicate that there, as expected, is no TKl mRNA in non- 
dividing lymphocytes from healthy persons. 
Due to the high TKl mRNA level in non-dividing CLL cells it was of importance 
to clarify whether the dominating TK in CLL cells was TKl or TK2, using the 
characteristic differences in phosphate donor specificity towards ATP and CTP. Both 
enzymes can utilize ATP, but only TK2 is capable of utilizing CTP9. The relative TK 
activity with CTP as phosphate donor was expressed as % of activity with ATP as 
phosphate donor. PHA-stimulated lymphocytes showed a 85-90% decrease in relative 
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activity, while non-dividing lymphocytes from healthy persons and lymphocytes from CLL 
patients showed a 7-30% decrease. The conclusion is that the enzyme in CLL cells is the 
same as in non-dividing lymphocytes from healthy persons, namely TK2. 
Table 1. Ratio of TKl mRNA copies and TK activity. 
TKl mRNA copies TK activity 
x 106/mg protein Units/mg protein 
TIC1 mRNA copies 
x 106/TK activity 
Non-dividing 
lymphocytes 
Lymphocytes from 
CLL patients 
< 0.06 0.009 c 6.7 
< 0.06 0.013 < 4.6 
0.21 0.013 16.2 
0.06 0.008 7.5 
< 0.06 0.009 < 6.7 
< 0.06 0.016 < 3.8 
10.3 0.008 1287 
7.4 0.006 1233 
22.7 0.013 1746 
15.2 0.005 3040 
6.1 0.006 1016 
The ratio between TKl mRNA and TK activity as estimated in non-dividing lymphocytes from 6 donors and 
in lymphocytes from 5 patients with CLL. The numbers refer to the individual donors and patients. 
1 unit is the amount of enzyme that phosphorylate 1 nmol substrate per minute. 
The occurence of a high level of TKl mRNA without concomittant expression of 
TKl enzyme activity may indicate that CLL cells have an abnormal regulation of the cell- 
cyclus regulated TKl. The regulations mechanism are not fully understood, but several 
investigations have shown that the changes in TKl mRNA during cell cycle can not fully 
account for the rise in TK activity. Translational and post-translational modifications may 
contribute to the regulation of TKl. Chang and Huang” have demonstrated that seryl 
residues of the TKl polypeptide are phosphorylated in cycling HL-60 cells. An increasing 
phosphorylation of the polypeptide was followed by an increase in enzyme activity, during 
the cell cycle. Another post-translational mechanism has been reported by Kauffman and 
Kelly”. They have shown that amino acid residues near the C-terminal end are 
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responsible for degradation of thymidine kinase protein in the G2 and M phase, and that 
mutations in this part of the gene allow expression in G, cells. 
It is possible that a post-translational mechanism serve as a secondary back-up system for 
the regulation of TK. This may explain why we can measure a high TKl mRNA level but 
no TKl activity. 
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Abstract-The level of cytosolic thymidine kinase (TKI) mRNA in lymphocytes from six healthy 
people and in lymphocytes from five patients with untreated chronic lymphatic leukemia (CLL) 
was determined with competitive polymerase chain reaction (competitive PCR). Using this 
procedure we have shown that in patients with CLL, there is an overexpression of TKI mRNA 
without corresponding enzymatic activity. The TKI mRNA level is approximately IOO-fold 
higher in lymphocytes from CLL patients than in lymphocytes from healthy persons. A high 
level of TKI mRNA without corresponding enzyme activity may indicate a defect in the 
processing of the enzyme. This may disturb the cells’ normal feedback system and thereby 
influence the development of malignant conditions. 
Key words: Thymidine kinase, mRNA;chronic lymphatic leukemia, competitive PCR, quanti- 
fication, CLL. 
Introduction 
Thymidine kinase (ATP: thymidine S’phospho- 
transferase E.C. 2.7.1.21) is a pyrimidine nucleoside 
salvage pathway enzyme with two isoenzymes: TKl 
and TK2, also called cytosolic and mitochondrial TK, 
respectively. Both enzymes catalyse the phosphoryl- 
ation of thymidine to TMP which is subsequently 
converted to TTP and utilized in DNA synthesis. 
TKl is the dominating form in dividing lymphocytes 
and TK2 is the only form present in non-dividing 
lymphocytes, but in low amounts [l]. The two iso- 
enzymes have characteristic differences in their 
enzyme kinetic pattern and subunit molecular 
weights [2,3]. TKl is cell-cycle regulated and the 
enzyme level is low or undetectable in quiescent (Go) 
cells, but increases dramatically when the cells enter 
S-phase [4-71. It is generally accepted that there is 
a close correlation between TKl activity and the 
proliferative state of the cell [I, 6, S-101. 
Abbreviations: CLL, chronic lymphatic leukemia; TK, 
thymidine kinase; TKl, thymidine kinase characteristic for 
dividing cells; TKZ, thymidine kinase characteristic for 
non-dividing cells; PCR, polymerase chain reaction; PHA, 
phytohemagglutinin; FCS, fetal calf serum; ATP, adeno- 
sine triphosphate; CTP, cytidine triphosphate. 
Correspondence to: Tina Kristensen or Helle Kock 
Jensen, at the above address. 
* The two first authors made equal contribution to this 
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Lymphocytes from patients with chronic lymphatic 
leukemia (CLL) are non-dividing and it is, therefore, 
plausible that the low TK activity in these cells almost 
exclusively is due to TK2. However, Munch-Petersen 
and Tyrsted found that the dominating TK activity 
isolated from lymphocytes from a CLL patient dis- 
played an enzyme kinetic pattern similar to that 
observed with TKl [ll]. 
The occurrence of TKl in quiescent CLL cells may 
be due to a change in the control of the cell-cycle 
regulated expression of the TKl gene. The cell-cycle 
regulation of TKl is a very complex system involving 
transcriptional, post-transcriptional [4,12,13], trans- 
lational and post-translational regulation mech- 
anisms [14,15]. To investigate the expression of TKl 
mRNA in CLL cells at the transcriptional level we 
have measured the level of TKl mRNA by the very 
sensitive competitive polymerase chain reaction 
(competitive PCR), and compared this with the TK 
enzyme activity. Surprisingly, we have found that 
the level of TKl mRNA in lymphocytes from CLL 
patients was about loo-fold higher than in lympho- 
cytes from healthy persons. 
Materials and Methods 
Materials 
3H-thymidine (2 Ci/mmol), [$*P]dCTP (3000 Ci/ 
mmol), Megaprime DNA labeling systems (RPN 1604) and 
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Hybond N+ membrane were from Amersham Denmark 
ApS. Isopaque-Ficoll was from Nycomed. RPMI-1640, 
fetal calf serum (FCS), phytohemagglutinin (PHA) and 
bovine serum albumin (BSA) were from Gibco. All nucleo- 
sides were from Boehringer and Mannheim, RNasin, ran- 
dom hexamer and M-MLV reverse transcriptase RNase 
H minus were from Promega. Thermus aquaticus DNA 
polymerase (AmpliTaq) was from Perkin Elmer/Cetus. 
The primers used were synthesized at the Department of 
Microbiology at the Technical University of Denmark. 
SpinBind DNA extraction Unit was from FMC Bio- 
products Europe. DEAE and 3MM filters were from What- 
man. All other reagents were of the highest quality gen- 
erally available. 
Cells 
Peripheral blood from six healthy persons was collected 
in heparin vacuum tubes. Peripheral blood, similarly col- 
lected from five patients with untreated CLL was kindly 
provided by Sven Erik Nielsen (M.D.), Roskilde Hospital. 
The lymphocytes were isolated by Isopaque-Ficoll gradient 
centrifugation [16] and washed in RPMI-1640 containing 
10% heat-inactivated FCS. The cell number was estimated 
in a Coulter counter and cell pellets were stored at -80°C. 
Phytohemagglutinin (PHA) stimulation of lymphocytes 
from healthy persons 
The lymphocytes were stimulated by PHA in RPMI-1640 
medium supplemented with 10% FCS, 20 pg/ml PHA and 
20 pg/ml penicillin/streptomycin, at a concentration of 
lo6 cells per ml in 5% CO2 at 37°C. For flow cytometry 
analysis aliquots of lo6 cells were centrifuged at 50 g for 
10 min and fixed in 250 pl buffer (6.1 mM glucose, 140 mM 
NaCl, 5 mM KCl, 2.7 mM Na2HP04, 1.1 mM KH2P04, 
0.5 mM EDTA) and 750 ~1 EtOH. The DNA was stained 
with 20 pg/ml EtBr and 10 pg/ml mithramycin and moni- 
tored by flow cytometry. In quiescent lymphocytes the S- 
fraction was about 8%. In lymphocytes cultured for 48 h 
with PHA the S-fraction was in the range of 30%. These 
data were in agreement with previous observations [17]. 
Extraction of lymphocytes for TK activity measurement 
The cells were suspended in Loebs buffer (20mM K- 
phosphate buffer (pH 7.4), 15% glycerol, 1 mM K-EDTA, 
10 mM dithiotreitol (DTT)), lysed by sonication (40 W, 
3 x 1-2s) and centrifuged at 20,OOOg for 30 min. The 
supematant (enzyme extract) was used for TK activity 
measurement and total protein measurement. 
TK activity assay 
TK activities were determined as initial velocities using 
the DEAE-cellulose 81 paper square method as previously 
described [2,3]. The standard assay mixture contained: 
50 mM Tris-HCl (pH 7.5), 10 mM Dm, 2.5 mM ATP, 
2.5 mM MgCl*, 3 mM NaF, 0.5 mM CHAPS (3-[(3-Chol- 
amidopropyl)-dimethylammonio]-l-propanesulphonate), 
3 mg/ml bovine serum albumin (BSA) and 10 PM 3H- 
thymidine (2 Ci/mmol). In assays with CTP as phosphate 
donor ATP was substituted with equimolar CTP. Samples 
of 13 ~1 were applied on DEAE filters 5, 10 and 15 min 
after starting the reaction by addition of enzyme extract to 
the assay mixture to a total volume of 50 ~1. The reaction 
temperature was 37°C. The filters were washed, eluted and 
the radioactivity determined by scintillation counting as 
described [3]. 
One unit of enzyme activity is defined as the amount of 
enzyme catalysing the formation of 1 nmol dTMP per min. 
Protein determination 
The protein content was measured by Coomassie bril- 
liant blue as described [18]. 
RNA isolation 
Total RNA was isolated using the guanidine thiocyanate 
method described by Chomczynski and Sacchi [19]. To 
improve purification an extra phenol extraction and alcohol 
precipitation was applied. RNA concentration was esti- 
mated from the optical density at 260 nm, and the RNA 
quality was examined by agarose gel electrophoresis. 
Estimation of RNA recovery 
3H-uridine was added to the growth medium (5 @ /ml, 
5 Ci/mmol) durin 
A total of 5 x 10 %  
PHA-stimulation in two experiments. 
labeled cells were harvested on 3 MM 
filters and non-incorporated 3H-uridine was washed away. 
From an equal number of cells, RNA was isolated and 
applied to 3 MM filters. The radioactivity on the filters 
was determined by scintillation counting. The amount of 
isotope in RNA was compared with the amount of isotope 
in the cells. The RNA recovery estimated from these 
comparisons was in the range of 70-90%. 
Reverse transcription 
RNA (2.5 ~1) was transcribed to cDNA in a 50 l.~l volume 
of PCR buffer (10 mM Tris-HCl (pH 8.3), 50 mM KCl, 
0.015% gelatine, 0.1% Tween 20)) 7.5 mM MgC12, 1 mM 
of each of the dNTPs, 40 U RNasin, 7 @4 random hex- 
amers and 250units of M-MLV reverse transcriptase 
RNase H minus. The reaction was terminated after 2 h at 
37°C. The extent of reverse transcription was controlled 
by a parallel reaction where 3H-lTP, instead of TTP was 
added. Aliquots of the reaction mixture were applied on 
3 MM filters. The non-incorporated 3H-lTP was removed 
from the filter by washing 3 x 10 min in 1 M  HCl containing 
0.6mM NaSP301,,, 10min in 0.26M NaAc/EtOH and 
finally in EtOH. The radioactivity was measured by scin- 
tillation counting (results not shown). 
Competitive PCR 
The principle in the competitive PCR method, as 
reported by Gilliand et al. [20], is a co-amplification of 
target cDNA concurrently with the corresponding genomic 
DNA. Thus, the two templates compete for the same 
substrates and primers ensuring equal efficiency of ampli- 
fication. The genomic DNA serves as internal standard. In 
our experiments we chose exons 1 and 2 with intron 1 from 
the TK gene as internal standard and exons 1 and 2 as 
the target cDNA fragment. The fragments were amplified 
using a pair of primers identical to those reported by Lipson 
and Baserga [21]. The sizes of the resulting fragments were 
138 bp with cDNA as template and 248 bp with genomic 
DNA as template. The internal standard of 248 bp genomic 
DNA was prepared by PCR with DNA as a template 
and using the primers mentioned above. The product was 
quantified by agarose gel electrophoresis together with 
different known amounts of DNA. The unknown amount 
of cDNA was estimated from a set of PCR reactions 
performed in a dilution series with known amounts of the 
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Fig. 1. Northern blot analysis of TKl mRNA. Total RNA 
was isolated from lymphocytes from donor 5 with 24 pg 
loaded in each lane. The lymphocytes were stimulated to 
grow with PHA. Non-stimulated (lane 1); 48 h (lane 2); 
72 h (lane 3); 96 h (lane 4); 168 h (lane 5). (A) Hybrid- 
ization with a TK probe detecting a single mRNA species 
of 1.5 kilobases. (B) After stripping the filter in (A) for 
TK probe, the filter was rehybridized to a probe for the 
constitutively expressed pactin, detecting a mRNA species 
Fig. 2. Cell-cycle-specific variation of TKl mRNA (copies/ 
mg protein) @  and TK activity (units/mg protein) n are 
illustrated for donor 1. The lymphocytes were stimulated 
with PHA for the indicated time periods. TKl mRNA 
was estimated by competitive PCR and TK activity was 
measured at standard conditions as described in ‘Methods’. 
of 2.1 kb. Results 
genomic DNA. The PCR products were separated by 
agarose gel electrophoresis. The amount of cDNA (in 
grams) in the sample was estimated as that amount (in 
grams) of genomic DNA giving equal intensity of the two 
amplification products. The number of TKl cDNA copies 
was calculated from the amount of cDNA, by division 
with the molecular weight of the 138 bp cDNA fragment 
(average molecular weight/base = 308). The number of 
copies of TKl cDNA was taken as being representative for 
the number of copies of TKl mRNA. 
The competitive PCR analyses were performed in a 25 ~1 
vol. of PCR buffer, 7 pmol of each primer, 200 PM of each 
dNTP, 1.5 mM MgCl* and 0.5 unit of Thermus aquaticus 
DNA polymerase. weat-denatured cDNA (lOO”C, 2 min) 
and internal standard were added to the reaction mixture 
with a layer of mineral oil to avoid evaporation. The 
amplification was performed in a Perkin-Elmer/Cetus 
Thermal Cycler according to the following program: de- 
naturation for 1 min at 95”C, annealing for 1 min at 60°C 
and polymerization for 1 min at 72”C, for 35 cycles. 
Northern blot 
Total RNA was prepared as described above. RNA 
preparations were denatured and electrophoresed through 
a 1.8% agarose gel containing 2.2M formaldehyde and 
transferred to a Hybond N+ membrane according to pub- 
lished procedures [22]. The probes used were human TKl 
cDNA from plasmid pTKl1 [23] and human pactin cDNA 
labeled with 32P-dCTP using Megaprime DNA labeling 
systems. The TKl probe was 720 bp and the actin probe 
was 400 bp. Non-incorporated nucleotides were removed 
with a SpinBind DNA extraction unit. In a 20 ml hybrid- 
ization reaction a 100ng (3.4 @Z/Kg) probe was used. 
Hybridization was performed according to the guidelines 
from Amersham Denmark ApS with high stringency wash- 
ing: 0.1 X SSPE-buffer (3.6 M  NaCl, 0.2 M  sodium phos- 
phate, 0.02 M  EDTA pH 7.7) and 0.1% SDS at 68°C. 
; 35 
“a Normal lymphocytes 
0.20 :g 
M 30- 5 s - 0.16 ii 
‘0 25 - 2 z 
m- - 0.12 Tz x .z 
0 48 12 96 168 
’ Induction with PHA (hours) 
Determination of TKl mRNA by Northern blotting 
Expression of TKl mRNA during the cell cycle of 
PHA stimulated lymphocytes was analysed for two 
donors by Northern blot analysis. As seen in Fig. 
l(A) it is clear that TKl mRNA is not expressed 
in quiescent lymphocytes, whereas a 1.5 kb band, 
corresponding to TKl mRNA, is seen in lymphocytes 
cultured with PHA. The level of TKl mRNA 
increases reaching a maximum after 96 h of culture 
with PHA, whereafter the level decreases. Hybrid- 
ization with a probe for the constitutive expressed p 
actin shows that equal amounts of RNA were applied 
to each lane. 
TKl mRNA and TK activity in lymphocytes from 
healthy donors 
With competitive PCR it is possible to measure 
TKl mRNA in quiescent lymphocytes. Figure 2 
shows the level of TKl mRNA (copies/mg protein) 
and the TK activity (units/mg protein) in lympho- 
cytes from donor 1. It is clearly demonstrated that 
the amounts of TKl mRNA and TK activity increase 
concomitantly during incubation of the lymphocytes 
with PHA, reaching a peak level at 96 h. The same 
cell-cycle regulated pattern was observed in lym- 
phocytes from the five other donors. Table 1 shows 
the actual amounts of TKl mRNA and TK activity 
in the six donors. In quiescent lymphocytes, the level 
of TKl mRNA is very low and in four out of six 
donors below the lim it of detection which in our 
reactions correspond to 0.006 copies of TKl mRNA/ 
cell. After PHA stimulation, the level of TKl mRNA 
transcripts increases to a maximum level, between 
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Table 1. The amount of TKl mRNA (copies/mg protein) and TK activity (units/mg protein) in 
non-stimulated lymphocytes and lymphocytes incubated with PHA for 96 h 
Donor 
No. 
TKl mRNA 
(copies X 106/mg protein) 
Non-stimulated PHA-stimulated 
lymphocytes lymphocytes 
TK activity (units/mg protein) 
Non-stimulated PHA-stimulated 
lymphocytes lymphocytes 
1 N.D 
2 ET5 
3 
4 0.061 
5 E:E 
6 
N.D = Not detectable. 
3.2 0.009 0.195 
4.9 0.013 0.120 
20.0 0.013 0.292 
5.4 0.008 0.503 
85.7 0.009 0.285 
98.8 0.016 0.760 
Table 2. The amount of TKl mRNA (copies/mg protein) 
and TK activity (units/mg protein) in lymphocytes from 
five patients with CLL 
CLL 
patient No. 
TKl mRNA 
(copies X 106/mg 
protein) 
: 10.3 7.4 0.008 6
3 22.7 0.013 
4 15.2 0.005 
5 6.1 0.006 
_ -- 1 2 3 4 5 
Fig. 3. The amounts of TKl mRNA (copies/mg protein) 
EI and TK activity (units/mg protein) n in lymphocytes 
isolated from CLL cells. The numbers on the x-axis refer 
to the five CLL patients. 
50 and 5000-fold higher than in quiescent cells. The 
broad range in TKl mRNA level may reflect indi- 
vidual variation between the different donors. 
TKl mRNA and TK activity in CLL cells The development of the PCR reaction has revo- 
Our results show that the TK activity in CLL lutionized the area of molecular biology. With its 
cells is low and in the same range as in quiescent high sensitivity, competitive PCR makes it possible 
lymphocytes, between 0.005-0.013 units/mg protein to measure gene expression of even a low copy gene, 
(Table 2). Surprisingly, despite the low TK activity, 
lymphocytes from CLL patients express very high 
levels of TKl mRNA (Fig. 3). The level of TKl 
mRNA/mg protein was between 30 and 300-fold 
higher than the level in quiescent cells from healthy 
donors. 
Characterization of the TK isoenzyme in CLL cells 
Owing to the high TKl mRNA level it was impor- 
tant to establish to which degree the TK activity was 
due to TKl or TK2. The low amounts of TK activity 
in the crude extracts, however, did not allow any 
further separation of TKl and TK2. Therefore, we 
have distinguished between TKl and TK2 using the 
pronounced differences in substrate specificity. 
Both isoenzymes utilize adenosine triphosphate 
(ATP) efficiently as phosphate donor, but TK2 can 
also use cytidine triphosphate (CTP) efficiently, 
whereas it is a poor phosphate donor for TKl [24]. 
To clarify whether the isoenzyme in CLL cells is 
similar to TK2 in quiescent cells or to TKl in dividing 
cells, we have compared the phosphate donor 
efficiency of ATP and CTP in quiescent lymphocytes, 
PHA stimulated lymphocytes and CLL ceils. TK 
activity with CTP as donor is given as a percent of 
TK activity with ATP as donor. 
As seen in Fig. 4, CTP was a poor phosphate donor 
for the TK enzyme in PHA stimulated lymphocytes, 
but an efficient phosphate donor for the TK enzyme 
in quiescent lymphocytes and CLL cells. These 
results indicate that the TK in CLL cells is the same 
as in quiescent lymphocytes, namely TK2. 
Discussion 
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Fig. 4. The ratio between phosphate donor capacity of 
CTP and ATP. In each experiment he enzyme activity is 
normalized to 100% with ATP as phosphate donor. (A) 
Non-stimulated lymphocytes; (B) lymphocytes 96 h after 
PHA stimulation; (C) CLL cells. The numbers on the X- 
axis refer to the individual donors and patients. 
such as thymidine kinase. We wanted to quantitate 
TKl gene expression in lymphocytes from untreated 
CLL patients, but were restricted by the limited 
availability of material. The most frequently used 
method for determination of gene expression is 
Northern blot analysis, but the results were very 
weak when carried out on PHA stimulated lym- 
phocytes. To be able to detect TKl mRNA in the 
very limited CLL samples, a more sensitive method 
was required. Using competitive PCR it was possible 
to quantify the level of TKl mRNA, even in quies- 
cent lymphocytes. We have estimated a very low, but 
detectable level, in two donors. The amount of TKl 
mRNA in quiescent lymphocytes is very close to the 
detection limit, which is about 0.006 copies of TKl 
mRNA/cell. Below this level, a 248 bp amplification 
product interferes with the competitive PCR. This is 
probably as a result of traces of DNA or non-spliced 
RNA in our RNA preparation. As there is a minor 
loss during the RNA purification and the cDNA 
synthesis (see Methods), the actual level of TKl 
mRNA is slightly underestimated. However, we pre- 
sume that the underestimation is in the same range 
in all samples, since we have used the same protocols 
for all donors. 
As a model system we have used human lym- 
phocytes which are truly Go cells. Culturing the 
quiescent lymphocytes in the presence of PHA stimu- 
lates the cells to enter the cell cycle, allowing events 
in the G i and S-phases to be investigated. A clear 
advantage of using lymphocytes as representatives 
for normal cells instead of immortal cell lines is the 
ability of cell lines to grow continuously. This is due 
to the occurrence of at least one feature required to 
turn normal cells into cancer cells. 
The expression of TK has been shown to be regu- 
lated on multiple levels and the regulation mech- 
anisms differ, depending on the cell system. For 
example, in cycling HeLa cells, the S-phase increase 
in TK activity is largely accounted for by an increase 
in the rate of TK protein translation [7]. In serum- 
starved cells stimulated to re-enter the cell cycle, the 
increase in TK activity is accompanied by a cor- 
responding increase in TKl mRNA. In this system 
both transcription and post-transcriptional mech- 
anisms account for the induction of TKl mRNA 
[4,25,26]. In PHA stimulated lymphocytes it is well 
known that TK activity increases dramatically when 
the cells enter the cell cycle [ 1,27,28]. However, for 
this cell system, we have not been able to find any 
reports regarding the fluctuations in TKl mRNA 
level as a characteristic of regulatory mechanisms. 
Our results show that both TKl mRNA and TK 
activity in PHA stimulated lymphocytes display the 
same cell-cycle regulated pattern as stimulated 
serum-starved cells. An increase in TKl mRNA in 
lymphocytes at the entry to S-phase is followed by 
an increase in TK enzymatic activity. The TKl 
mRNA level increases about loo-fold when the cells 
are stimulated. When cells leave S-phase, the TKl 
mRNA level and TK enzyme activity decrease. 
An important difference between the two cell sys- 
tems is that lymphocytes are truly Go cells, they do 
not enter S-phase before 48 h after addition of PHA. 
This is in contrast to stimulated serum-starved cells 
which reach S-phase after 12 h [25]. 
In CLL cells we found, surprisingly, that TKl 
mRNA expressed per mg protein is 30-300 fold 
higher than in quiescent lymphocytes. The TK 
activity level is very low and in the same range as 
in quiescent lymphocytes. Exploiting the different 
substrate specificities of TKl and TK2 using CTP 
instead of ATP as phosphate donor, it was shown 
that the TK activity in the CLL cells is due to TK2. 
This phenomenon of a high TKl mRNA level with 
no TKl enzyme activity has to our knowledge not 
been described elsewhere. 
Our experiments indicate that CLL cells have an 
abnormal regulation of the S-phase-regulated TKl. 
TKl mRNA level is high and is prevented from 
translation into active enzyme. Owing to its associ- 
ation with the proliferative state of cells, TK activity 
is regarded as a useful tumor marker with prognostic 
value for a number of malignant diseases such as 
human breast cancer [29-311, non-Hodgkins lym- 
phoma [32] and acute lymphatic leukemia [33]. In 
CLL cells the TK activity is very low and can, there- 
fore, not be used as a tumor marker. On the other 
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hand, the level of TKl mRNA is very high and may, 
therefore, serve as an alternative tumor marker in 
these cells to predict the diagnosis at an earlier stage. 
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ALTERED KINETIC PROPERTIES OF RECOMBINANT HUMAN CYTOSOLIC 
THY-MIDINE KINASE (TKl) AS COMPARED WITH THE NATIVE FORM. 
Helle Kock Jensen and Birgitte Munch-Petersen. 
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DK 4000 Roskilde, Denmark. 
INTRODUCTION 
Human cytosolic thymidine kinase (TKl) is a cell cycle regulated key enzyme in the 
salvage pathway of the nucleoside metabolism catalyzing the first phosphorylation step in 
dlTP synthesis. Thymidine kinase (TK) is an enzyme of high interest, primarily because of 
the specific cell cycle regulated expression. In addition, TK phosphorylates a number of 
nucleoside analogs which in the phosphorylated form interfere with DNA replication and 
repair and hence are useful in the chemotherapeutic treatment of cancer and viral infections. 
A more detailed knowledge of TK will be valuable for constructing more TK specific and 
efficient nucleoside analogs. A main problem in the structural an physical investigation of TK 
is the extremely low level of TK protein in mammalian cells. In this work we describe an 
expression vector for human TKl . Surprisingly, the enzymatic properties of the recombinant 
TKl differ from those of the native TKl with respect to the recently described specific 
regulatory effect of ATP’. This may indicate that native TKl is subject to posttranslational 
modifications, such as phosphorylation, modifications that are not operable in E.&i. 
METHODS. 
Conhction of TKl-pet3a vector. 
The TKl-pet3a vector was constructed by standard methods2 by inserting the amino-acid 
coding region of the human TKl into the polylinker of the pet3a vecto8 which is under 
control of a T7 RNA polymerase promotor. The aminoacid coding region was PCR amplified 
from the pTKI14 containing the complete human TKl cDNA. The two primers in the PCR 
flank the aminoacid coding sequence and each has a restriction site in the 5’ end (NdeI and 
BamHI, respectively). The PCR product was blunt-end ligated into the EcoRV site of 
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pBR322. This cloning was nessesary because it was not possible to cut the amplified product 
directly by NdeI and BamHI. The pBR322 with the insert was cleaved by BamHI and NdeI 
and the insert was purified by agarose gel electrophoresis and band purification by standard 
methods2. The insert and the pet3a vector were ligated and used to transform a host E.coli 
(HB 101). The TK 1 -pet3a vector was isolated and sequenced by T7 DNA polymerase to 
control that no mutations had occurred during the PCR. 
Expression of TKl. 
E.coli strain BL2l@E3)lysS containing T7 RNA polymerase under control of the IPTG 
inducible UV5 promotor was transformed by the TKl-pet3a vector. The expression was 
carried out in LB medium (10 g tryptone, 5 g yeast, 10 g NaCl/liter) at 25°C. When OD6, 
was 0,2, IPTG was added to a final concentration of 0,4 mM to induce the UV5 promotor. 
The cells were harvested by centrifugation (14,000 g, 3 min), resuspended in l/4 vol of lysis 
buffer (50 mM Tris-HCl @H 8), 1 mM EDTA, 100 mM NaCl, 0.5% Nonidet P-40, 5 mM 
DTT, 0.5 mM PMSF, 5 mM Benzamidine, 10% glycerol, 50 mM NaF) and sonicated 3 
times 15 set (40 Watt) on ice. Cell debris was removed by centrifugation 20,000 g at 4°C for 
30 min. 
Purification of TKl. 
All steps in the purification were performed essentially as de&bed’. Enzyme extract 
from 1 liter culture was filtered on a G-25 column (5.5 x 20 cm) and the enzyme 
chromatographed on a 3’-dTMP-Sepharose column (1 x 4 cm). 
For enzyme kinetics studies, thymidine was removed by CM-sepharose chromatography 
as described’. E.coZi TK is removed together with thymidine in this step, because in contrast 
to the human TK, it does not bind to the negative carboxy group?. 
Enzyme kinetics. 
The thymidine kinase activity was assayed by the DEAE-cellulose 81 paper method7. 
Standard assay conditions were: 50 mM Tris-HCl, pH 8, 2.5 mM MgC&, 10 mM 
dithiothreitol, 3 mg/ml BSA, 2.5 mM ATP, 10 PM radiolabelled thymidine. One unit of 
enzyme activity is defined as the amount of enzyme that can phosphorylate 1 @mol of 
nucleoside per min at 37°C under standard assay conditions. K, values and Hill coeficients 
were determined from Hill plots (log v/(V-v) versus log s). 
Sephadex 6-200 chromatography. 
Sephadex G-200 superfine was swelled and packed according to standard procedures (600 
x 20 mm). V, values were determined for five marker proteins (beta-amylase (200 KD), 
alcohol dehydrogenase (150 KD), bovine serum albumin (66 KD), carbonic anhydrase (29 
KD), cytochrome C (12,4 KD)) and for TKl in absence and presence of ATP. Before 
determinating the V, value in the presence of ATP the enzymes were preincubated with 2.5 
mM ATP and the column was pre-equilibrated with buffer containing 2.5 mM ATP. 
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RESULTS AND DISCUSSION. 
An expression-vector was constructed to ensure unmodified ends of the TKl. When 
BL21(DE3)lysS is transformed by this vector the yield is around 1 mg TKl per liter culture 
(25”C, 24 hours). 
The recombinant TK was purified by affinity chromatography on a 3’-dTMP-Sepharose 
column to more than 95 % homogeneity as estimated from a SDS-PAGE (figure 1). The sub- 
unit molecular weight was as expected, similar to the native TKl - around 24 KD. 
Figure l.SDS-PAGE of purified 
recombinant TK 1. Lane 1: 
Proteinmarker (97 KD, 66 KD, 
45 KD, 31 KD, 21 KD, 14 KD), 
lane 3: Bacteria lysate, 
lane 4: Wash fractions of 
aftinity column, lane 6: 
Eluate from affinity column. 
1 n- - - 4 6
Table l.Comparison of the properties of lymphocyte TKl and recombinant TKl. 
* Hill coefficient = n 
Lymphocyte TKl Recombinant TKl 
I I 
Spec. act. 9.500 10.000 
nmol/min/mg 
+ATP 0.5 0.4 
% (PM) 
-ATP 12 0.4 
Hill +ATP 
coeffi 
cient -ATP 
Subunit 
molecular mass (KD) 
1.25 1.5 
0.7 1.4 
24 24 
Native +ATP 150 150 
molecular 
mass -ATP 70 150 
The kinetic data for the native TKl (Table 1) are in agreement with our previously 
reported data, and show that incubation or storage with ATP induces a kinetically slow 
transition from a low affinity form (Km= 12pM, n=0.7) to a high affinity form of TKl 
(Km=0.5 FM, n= 1.25)‘. For the recombinant enzyme, the Km and n values were 0.4 PM 
and 1.4 - 1.5, respectively, for both the -ATP and +ATP form. This indicates that the 
recombinant enzyme only occurs as the high affinity form with the low Km value. In addition 
the Hill coefficients of 1.4 - 1.5 indicate a slightly higher degree of positive homotropic 
cooperativity than found for the +ATP form of the native TKl. 
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The different kinetics of the + ATP and -ATP forms were related to the ability of the 
native TKl to appear as a dimer in the absence of ATP and a tetramer in the presence of 
ATP’. When the apparant molecular weights of the native and recombinant TKl were 
determined in absence and presence of ATP (figure 2), we found that recombinant TKl was 
a tetramer also in absence of ATP. 
10003 I 
Lymphocyte TKl tATP 
20 25 30 35 40 45 51 
Figure 2. The molecular weight 
determined by G-200 superfine 
Sephadex. The column is calibrated by 
protein standards (12 - 200 KD) marked 
as black squares. The recombinant and 
lymphocyteTK1 preincubatedwithand 
without ATP are marked with black 
arrows. 
I 
Fr action numbers 
Two conclusions are implicated in these results: Firstly the ATP induced kinetic transition 
of the native TK1 is associat& with the dimer-tetramer transition. Secondly, the missing 
ability of recombinant TKl to undergo the ATP induced transition between’ two distinct 
molecular forms, may be due to the lack of post-translational modifications when expressed 
in E.coZi. Such modifications may enable native TKl to undergo the reversible transition, and 
we find it likely that this mechanism is involved in the cell cycle regulated expression of TKl 
as previously suggested’>*. I 
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ABSTRACT 
An expression system for human W'cytosoliclt thymidine kinase 
(TKI) in E.coli was developed. cDNA encoding the entire 
polypeptide of TKl was inserted in the polylinker of the pet3a 
vector and expressed in BL21(DE3)lysS. The yield was about 1 
mg/liter culture after 24 hours of induction at 25°C. The TKl 
enzyme was purified to homogeneity by thymidine affinity 
chromatography. The recombinant TKl has the samme sub molecular 
weight and specific activity as the native enzyme (purified from 
PI-IA stimulated lymphocytes). Also, when stored in ATP, 
recombinant and native thymidine kinase were identical with 
respect to thymidine kinetics as a high affinity form (K, = 0.5 - 
0.7 PM) and molecular size as a tetramer. Surprisingly, this was 
not the case when storing the enzymes without ATP. Thus, as shown 
recently, the native enzyme is a dimer with low affinity for 
thymidine (K, = 15 pM)(Munch-Petersen,B., Tyrsted,G. and Cloos,L. 
(1993) The Journal of Biological Chemistry. 268, 15621-15625). 
Recombinant TKl were a tetramer both in presence and absence of 
ATP and solely showed the kinetics of a high affinity form. The 
lack in ability to appear as the low affinity dimer may be due to 
different posttranslationalmechanisms in human cells and E.coli. 
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INTRODUCTION 
Human cytosolic thymidine kinase (TKl) (ATP: thymidine 
5'phophotransferase E.C. 2.7.1.21) is a cell cycle regulated key 
enzyme in the salvage pathway of the nucleoside metabolism, 
catalyzing the first phosphorylation step in TTP synthesis. TKl 
is an enzyme of high interest, primarily because of the specific 
cell cycle regulated expression, involving transcriptional, post- 
transcriptional (Coppock & Pardee, 1987)(Gudas et al, 
1988)(Groudine & Casimir, 1984), translational and post- 
translational regulation mechanisms (Ito & Conrad, 1990)(Sherley 
& Kelly,l988)(Kaufman & Kelly,1991). In addition, TK 
phosphorylates a number of nucleoside analogs used in 
chemotherapeutic treatment of cancer and viral infections. In the 
phosphorylated form the analogs interfere with DNA replication 
and repair and abolish the cellular proliferation. 
The amount of TKl is extremely low in human tissues. 
Furthermore, the availability of human tissue is limited and it 
is very timeconsuming and expensive to purify TKl. In addition 
the enzyme is very unstable especially in the pure form. These 
factors encouraged us to construct an expressionvector in E.coli. 
In this report we describe the expression of TKl, the 
purification and characterization of the recombinant enzyme as 
compared to the native form. The specific activity and sub 
molecular weight were the same as found for the native TKl 
purified from human lymphocytes. 
Recently Munch-Petersen et al (1993) found a specific 
reversible effect of ATP on TKl, purified from human lymphocytes. 
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After preincubation or storage with ATP (+ATP form) the native 
TKl appear as a high affinity form (K, = 0.5 PM) and changes 
reversible to a low affinity form (K, = 15 PM) by removal of ATP 
(-ATP form). Furthermore, the -ATP form of native TKl is a dimer, 
and the +ATP form is a tetramer of 24 kDa. We investigated 
recombinant TKl both incubated with ATP and without ATP. 
Recombinant TKl has the molecular size as a tetramer and 
thymidine substrate kinetics identical to the +ATP form of native 
TKl. Surprisingly, the recombinant TKl was not able to change to 
the dimer conformation and low affinity kinetics when ATP was 
removed from the enzyme. Recombinant TKl is a tetramer and appear 
as the high affinity form both in absence and presence of ATP. 
This may indicate that native TKl is subject to posttranslational 
modifications, such as phosphorylation, modifications that are 
not operable in E.coli. 
MATERIALS AND METHODS 
Materials. 
E.coli strains: BL21(DE3)lysS, BL21(DE3)lysE, KY895 (Igarashi et 
6 1967) and HBlOl. 
Plasmids: pBR322, pET3a (Studier et a1,1990) and pTKl1 (Bradshaw 
& Deininger,l984). 
3H-thymidine (25 Ci/mmol), 3H-3/-azidothymidine (3H-AZT) (14 
Ci/mmol), 3H-2'-arabinosol-thymidine (3H-AraT) (6 Ci/mmol) and [Q- 
3sS] dATP(lOOO Ci/mmol) were from Amersham ApS Denmark. 
Enzvmes: EcoRV, NdeI and BamHI were from New England Biolab, 
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ligase and Klenow polymerase from Promega and Taq polymerase from 
Perkin Elmer. 
Oliaonucleotides: pOliII1 was kindly provided by Dr. Reinhold 
Hofbauer. pP4, pP5, pFB, pF2, pBaf2 and pBaf1 were from DNA 
Technology ApS, DK. 
pOliII1: 5, GCACTGGATGGGACCTTCCAGAGGAAG 3, (sense) 
pP4: 5, ACACATATGAGCTGCATTAACCTGCCCACTGTG 3' (sense) 
pP5: 5, CACGGATCCTCAGTTGGCAGGGCTGCATTGCAG 3, (antisense) 
pFB: 5, ACACATGACCGGAACACCATGGAGGC 3, (sense) 
pF2: 5, GTCATAGGCATCGACGAGGGGCAGTTT 3, (sense) 
pBaf2: 5, GTCAGCTTCACCACGCTCTC 3' (antisense) 
pBaf1: 5, CGGTCATGTGTGCAGAAGCT 3, (antisense) 
Columns: G-25 sepharose, 3,-dTMP-sepharose, Carboxymethyl 
sepharose and G-200 sephadex superfine were from Pharmacia. 
Nucleotides were from Boeringer Manheim. 
DNA sequencing kit was sequenase version 2.0 from United States 
Biochemical Corporation. DEAE filters were from Whatman. 
Protein markers were from Sigma. 
All other reagents were of the higest quality available. 
Buffers. 
Lvsisbuffer: 50 mM Tris-HCl (pH 8)' 1 mM EDTA, 100 mM NaCl, 0.5% 
Nonidet P-40, 5 mM DTT, 0.5 mM PMSF, 5 mM Benzamidine, 10% 
glycerol, 50 mM NaF. 
Buffer A: 20 mM Tris-HCl (pH 8)' 5 mM MgC&, 5 mM NaF, 10% 
Glycerol, 5 mM Dithiothreitol (DTT), 0.5 mM CHAPS, 5 mM 
Benzamidine, 0.5 mM PMSF. 
Buffer B: 10 mM Tris-HCl (pH 7), 5 mM MgC12, 5 mM NaF, 10% 
Glycerol, 5 mM DTT, 0.5 mM CHAPS, 5 mM Benzamidine, 0.5 mM PMSF. 
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Buffer C: Buffer B + 1 mM thymidine 
Buffer D: 10 mM Tris-HCl (pH 7)' 5 mM MgC&, 10 % glycerol, 5 mM 
DTT. 
Buffer E: 100 mM Tris-HCl (pH 8)' 5 mM MgCl,, 10% glycerol, 5 mM 
DTT, 0.5 mM CHAPS, 100 mM KCl. 
Buffer F: 50 mM Tris-HCl (pH 7.5), 5 mM MgCl,, 100 mM KCl, 5 mM 
DTT. 
Construction of the TKl-net3a vector. 
The TKl-pet3a vector (figure 1) was constructed by standard 
methods (Sambrook et a1,1989) by inserting the amino-acid coding 
region of the human TKl into the polylinker of the pet3a vector 
(Studier et al, 1990) which is under control of a T7 RNA 
polymerase promotor. The aminoacid coding region was PCR 
amplified from the pTKl1 (Bradshaw & Deininger, 1984) containing 
the complete human TKl cDNA. The two primers in the PCR flank the 
aminoacid coding sequence and each has a restriction site in the 
5' end (NdeI and BamHI, respectively). After blunt-ending the PCR 
product with Klenow polymerase the PCR product was blunt-end 
ligated into the EcoRV site of pBR322. This cloning was nessesary 
since it was impossible to cut the amplified product directly by 
NdeI and BamHI. The pBR322 with the insert was cleaved by BamHI 
and NdeI and the insert was purified by agarose gel 
electrophoresis and band purification by standard methods 
(Sambrook et al, 1989). The insert and the pet3a vector were 
ligated and used to transform a host E.coli (HBlOl). The TKl- 
Paper IV, side 6 
pet3a vector was isolated and sequenced by the ddNTP chain 
terminating method (Sanger et al, 1977) to ensure that no 
mutations had occurred during the PCR and that the base sequence 
was identical the published sequence for human TKl (Bradshaw & 
Deininger, 1984). The sequencing strategy is illustrated in 
figure 2. 
Expression of TKl. 
E.coli strain BL21(DE3)lysS containing T7 RNA polymerase 
under control of the IPTG inducible W5 promotor was transformed 
by the TKl-pet3a vector. The expression was carried out in LB 
medium (10 g tryptone, 5 g yeast, 10 g NaCl/liter) at 25'C. When 
OD,, was 0'2, IPTG was added to a final concentration of 0,4 mM 
to induce the W5 promotor. The cells were harvested by 
centrifugation (14,000 g, 3 min), resuspended in l/4 vol of lysis 
buffer and sonicated 3 times 15 set (40 Watt) on ice. Cell debris 
was removed by centrifugation 20,000 g at 4OC for 30 min. 
Purification of TKl. 
All steps in the purification procedure were performed 
essentially as described (Munch-Petersen et a1,1991). The enzyme 
extract from one liter culture was filtered on a G-25 column (55 
mm x 200 mm) with buffer A and the desalted enzyme fractions were 
chromatographed on a 3/- dTMP-sepharose column (10 mm x 40 mm) 
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pre-equilibrated with buffer A. After washing the affinity column 
with buffer A and B, TKl was eluted with buffer C. Fractions of 
3 ml were collected. 
For enzyme kinetics studies, thymidine was removed from the 
enzyme by CM-sepharose chromatography (Munch-Petersen et al, 
1993). The column (10 mm x 20 mm) was washed with buffer D, and 
TKl eluted with buffer E. E.coli TK was removed together with 
thymidine in this step, since this enzyme does not bind to the 
negative carboxy groups (Okazaki & Kornberg,l964). The enzyme 
fractions from the CM column were divided in two and 2.5 mM ATP 
was added to one of these. The ATP containing enzyme fraction was 
referred to as the +ATP form, and the ATP free fraction as the - 
ATP form. 
TK activity assav. 
TK activity was determined as initial velocities using the 
DEAE-cellulose 81 paper square method as described (Munch- 
Petersen,l984)(Munch-Petersen et a1,1991). The standard .assay 
mixture contained: 50 mM Tris-HCl (pH 7.5), 10 mM DTT, 2.5 mM 
ATP, 2.5 mM MgCl,, 3 mM NaF, 0.5 mM CHAPS, 3 mg/ml bovine serum 
albumin (BSA) and 10 I.IM 3H-thymidine (2 Ci/mmol). After addition 
of enzyme extract to the assay mixture to a total volume of 50 
~1, samples of 13 1.11 were applied on DEAE filters after 5, 10 and 
15 min of reaction at 37OC. The filters were washed with 5 mM 
ammoniunformiate, eluted by 0.2 M KCl/O.l M HCl and the radioac- 
tivity determined by scintillation counting as described (Munch- 
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Petersen et a1,1991). 
The thymidine and ATP data were analysed by Hofstee plots 
(v versus v/s). Thymidine kinetics by Hill plots (log v/(V,,-v) 
versus log s). The TTP inhibition were determined as Is0, which is 
the inhibitor concentration at 50% inhibition. 
Senhadex G-200 chromatosranhv. 
Sephadex G-200 superfine was swelled and packed according to 
standard procedures (20 mm x 600 mm) and the chromatography was 
performed with buffer F. The elution fraction number (V, values) 
were determined for five marker proteins (beta-amylase (200 KD), 
alcohol dehydrogenase (150 KD), BSA (66 KD), carbonic anhydrase 
(29 KD), cytochrome C (12,4 KD)) and for the enzymes in absence 
and presence of ATP. When determinating the enzymes value in the 
presence of ATP, the enzymes were preincubated with 2.5 mM ATP, 
the column was pre-equilibrated and the elution performed with 
buffer F containing 2.5 mM ATP. 
Other methods. 
Protein concentrations were determined by coomassie 
brilliant blue as described (Bradford, 1976) with BSA as the 
standard protein. 
The sub-unit molecular weight of TKl was determined by SDS- 
polyacrylamide gel electrophoresis (SDS-PAGE) with a 4.5% 
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stacking gel and a 15% separation gel prepared by standard 
methods (Sambrook et al, 1989). The samples were denatured at 
95°C for 3 min in 125 mM Tris-HCl, 10 mM DTT, 1% SDS, 0.01% 
Bromphenol Blue and 25% glycerol before loading on the gel. The 
protein bands were visualized by Coomassie brilliant Blue or 
silver staining and dried on a slab gel drier for 2 hours at 
80‘32. 
The TKl vector was sequenced by the Sequenase DNA 
sequencing kit using 35S-ATP and the primers listed in MATERIALS. 
The sequencing polyacrylamide gels were prepared by standard 
methods (Sambrook et al, 1989). 
RESULTS 
An expression-vector for direct expression of TKl was 
constructed as outlined in figure 1 and sequenced by the 
sequencing-strategy shown in figure 2. As the sequence was 
identical to the published sequence for TKl (Bradshaw & 
Deininger,l984), we conclude that no mutations had occurred 
during the initial PCR. 
When BL21(DE3)lysS is transformed by this vector and the 
expression of TKl is induced by IPTG, the yield is around 1 mg 
per liter culture. Initially we attempted to transform an E.coli 
TK minus strain, KY895, but it was notpossibleto transform this 
strain by the vector. We also tried to transform a strain 
suitable for the expression of toxic genes, BL21(DE3)lysE. But 
induction of this transformant resulted in a yield 20 fold less 
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the yield obtained with BL21(DE3)lysS. 
The recombinant TKlwas purified by affinity chromatography 
to more than 95% homogeneity as estimated from an SDS-PAGE 
(figure 3) and the sub-unit molecular mass was about 26 kDa as 
predicted from the cDNA sequence and slightly above that of the 
native TKl - which is about 24 kDa. The specific activity of the 
recombinant TKl was similar to the native TKl about 10 
pmol/min/mg. 
In a recent investigation of the enzymatic properties of 
purified TKl from human lymphocytes we uncovered a hitherto 
unrecognized property (Munch-Petersen et al, 1993). When ATP was 
removed from the pure enzyme, the kinetics with thymidine changed 
remarkably from a high affinity kinetics with a low K, value of 
0.5 - 0.7 j&M to a low affinity kinetics with a high K, of 15 PM. 
The low affinity kinetics was non-Michaelis-Menten, with biphasic 
curves in Hofstee plots (v versus v/s). The high affinity form 
was regained after incubation or storage in ATP of the low 
affinity form. A second removal of ATP restored the low affinity 
form. Thus, the ATP effect was reversible. Since the native TKl 
eluted as a dimer in the absence and a tetramer in the presence 
of ATP, it was concluded that the low affinity kinetics was 
associated with the dimer and the high affinity kinetics to the 
tetramer. The biphasic kinetics was explained as the simultaneous 
presence of the high and low affinity enzyme forms in a ratio 
dependent on the thymidine and enzyme concentrations. 
Previous investigations of the kinetics of mammalian TKl 
have normally been performed on the ATP form, since ATP has 
routinely been used to stabilize the otherwise extremely unstable 
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enzyme (Sherley and Kelly, 1988; Ellims et al, 1982; Gan et al, 
1983; Munch-Petersen, 1984; Munch-Petersen etal, 1991). For this 
reason, the properties of the -ATP form and the reversible effect 
of ATP have not been described before. 
In the present work we wanted to investigate if the 
recombinant TKl had the same reversible properties with ATP as 
the native TKl. In addition, we wanted to compare the properties 
of the native and recombinant TKl regarding the ATP and TTP 
kinetics and the substrate specificity towards the thymidine 
analogs, AZT and ara-T. The data for the comparison of the 
properties of recombinant and native TKl are shown in table 1. 
The acitivities of the recombinant TKl with the thymidine 
analogs, AZT and ara-T were identical to those obtained with the 
native TKl. With 5 /.LM of AZT the activity of the +ATP and -ATP 
form of recombinant TKl was 46% and 38%, respectively, of the 
activity obtained with 5 PM thymidine. Ara-T was not 
phosphorylated by recombinant TKl. These data was in complete 
agreement with previous data for the native enzyme (Eriksson et 
a1.1991; Munch-Petersen et a1.1991). 
When investigating the ATP substrate kinetics at 10 PM 
thymidine, both the +ATP and -ATP form of recombinant enzyme 
showed a positive cooperative kinetics with a K, of about 30 PM. 
This is quite similar to the +ATP form of native TKl where K, is 
about 14 PM but very diverging to the -ATP form where K, is about 
140 /.JM. 
Examining the inhibitory effect of TTP at 10 PM thymidine 
showed surprisingly that the recombinant TKl is around 10 times 
more sensitive to TTP than the native TKl. This was investigated 
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by varying the TTP concentration. As the inhibition was 
cooperative for both recombinant and native TKl, the sensitivity 
to TTP was expressed by IS0, where I,, is the TTP concentration 
necessary for 50% inhibition. Recombinant TKl has a ISo value at 
about 1,5 PM TTP whereas the native TKl has a IS,, value at about 
10 PM. In these experiments both the +ATP and -ATP forms of 
recombinant and native TKl showed identical results. 
The thymidine substrate kinetics of the +ATP form of 
recombinant TKlwas Michaelis-Menten type with a straight line in 
the Hofstee plot of v versus v/s (figure 4), and a K,,, value of 
0.4 PM. This pattern was identical to that found with the native 
TKl. However, as indicated from figure 4, the -ATP form of 
recombinant TKl showed exactly the same kinetics as the +ATP 
form, with Michaelis-Menten kinetics and Q=O.4 PM. The Hill 
coefficents for the +ATP and -ATP form of recombinant TKl were 
1.5 and 1.4 respectively, and thus slightly higher than the Hill 
coefficient of 1.2 found for the +ATP form of native TKl. 
This indicated that the recombinant TKl solely occurred as 
the high affinity form both in the absence and in the presence of 
ATP. 
The different thymidine substrate kinetics of the -ATP and 
+ATP forms of the native TKl were related to the different 
molecular mass of the two forms. Thus the molecular mass of the 
native TKl as determined by elution on Superose 200 was a dimer 
(50 kDa) in the absence of ATP and a tetramer (100 kDa) in the 
presence of ATP. This indicates that ATP induces a 
tetramerization of the 24 kDa TKl from human lymphocytes (Munch- 
Petersen et a1,1993). 
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In the present work we have determined the apparant 
molecular mass of the native and recombinant TKl by elution on G- 
200 sephadex. The results are shown in figure 5. In absence and 
presence of ATP the apparent molecular mass of the native TKl 
were 75 kDa and 175 kDa respectively. The recombinant TKl 
however, exclusively appeared with the high molecular mass. The 
apparent molecular mass in absence and presence of ATP were 
identical and about 155 kDa. This indicates that the ability to 
dissociate from a tetramer structure to a dimer structure was 
lost in the recombinant TKl. 
DISCUSSION. 
As outlined in RESULTS we tried to express the TKl-pET3a 
vector in a E.coli TK minus strain (KY895) to obtain an 
expression system without any interfering bacterial TK, but we 
were not able to transform this strain. As there were no problems 
with transforming the strain with other vectors, we assume that 
the TKl-pET3a vector were toxic for the strain. The next attempt 
to express the vector was in a strain permissive for toxic genes 
(BL21(DE3)lysE). The 1ysE plasmid has a high transcription of 
lysozyme inhibiting T7 RNA polymerase. This gave an expression of 
50 pg/liter culture. Finally we transformed BL21(DE3)lysS 
containing the 1ysS plasmid which have a low expression of 
lysozyme with the TKl-pET3a vector and achieved a yield of 1 
mg/liter culture. These results indicate that only a moderate 
direct expression of human TKl is tolerated by E.coli otherwise 
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it is toxic to the cell. 
The recombinant TKl was very unstable during purification. 
As the yield was improved by addition of proteinase inhibitors, 
we assume that the increased instability as compared to the 
native TKl is owned to proteinases from E.coli. The binding 
properties of recombinant TKl to TMP sepharose and CM sepharose 
were similar to the native TKl as recombinant TKl was purified 
with exactly the same procedures as used for the native TKl and 
with a yield of 25 - 50%. 
By examining both the +ATP and -ATP form of recombinant TKl 
we found identical specific activity and substrate specificity 
with two nucleoside analogs compared to the results with native 
TKl. There were no differences between the +ATP and -ATP form. 
This was also the case when the ATP and TTP kinetics were 
investigated. However, recombinant TKlwas 10 fold more sensitive 
towards TTP as compared to native TKl. 
Regarding the thymidine substrate kinetics, the +ATP form 
of the recombinant TKl had similar properties as the native TKI. 
The K, values were low, 0.5 PM, and the kinetics was Michaelis- 
Menten. Unexpectedly, the kinetic properties of the -ATP form of 
the recombinant TKl were identical to those of the +ATP form, and 
the biphasic kinetics with the high K, value was not observed, in 
contrast to what was obtained with the -ATP form of the native 
TKl (Munch-Petersen et al, 1993) (figure 4). 
The similarity of the +ATP and -ATP form of the recombinant 
TKl was also reflected in the gel-filtration studies. Here, like 
the native TKl, the recombinant TKl eluted as a tetramer in the 
presence of ATP. But when eluted in the absence of ATP, the 
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recombinant TKl maintained the tetramer form, whereas native TKl 
dissociated to a dimer (figure 5). 
As mentioned in results, we achieved higher apparant 
molecular weights of the native TKl by elution on G-200 sephadex 
than in the previous elution experiments with the same enzyme 
preparation on superose 12 (Munch-Petersen et a1.1991; 
Munch-Petersen et a1.1993). This may be due to a non-globular 
shape of the proteins resulting in different filtration on the 
two column matrices. Similarly, the slightly lower molecular mass 
of recombinant TKl (155 kDa) as compared to the native TKl (175 
kDa) may be explained by an altered conformation of the tetramer. 
As the recombinant TKl can not dissociate to a dimer, a tighter 
association of the four sub-units is probable. 
In the previous investigation of the native TKl, the 
biphasic kinetics obtained with the ATP free enzyme form was 
explained as the result of the simultaneous presence of two 
enzyme forms, a dimer with low affinity and a tetramer with high 
affinity (Munch-Petersen et a1.1993). The observation in the 
present study that the ATP free form of recombinant TKl is a 
tetramer with a Michaelis-Menten type of thymidine kinetics, 
supports the previous connection of the kinetic pattern with the 
molecular mass. 
Recently Chang et al (1994) has showed that TKl from HeLa 
cells is differentially phosphorylated during the cell cycle and 
that this phosphorylation affects the TKlactivity. They document 
that mitotic arrested HeLa cells had a hyperphosphorylated low 
affinity form of TKl (K, = 15.5 PM) and dividing HeLa cells had 
a hypophosphorylated high affinity form of TKl (K, = 1.5 PM). 
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They show that in HeLa cells a Staurosporine sensitive mitotic 
kinase was responsible for the mitotic phosphorylation. 
The K, values for the +ATP and -ATP form of the pure native 
TKl were 0.5 - 0.7 and 15 PM, respectively (Munch-Petersen et 
a1,1993). Therefore it is very likely that these two forms are 
similar to the differentially phosphorylated forms found by Chang 
et al (1994) in G,/S phase cells and in mitotic arrested cells, 
respectively. As the K, of the +ATP and -ATP form of recombinant 
TKl are identical, this further implies that the recombinant TKl 
have lost the ability to shift form. 
One question remains to be answered. Chang et al (1994) 
suggested that a kinase catalyzed phosphorylation is needed for 
the shift from the high affinity hypophosphorylated form to the 
low affinity hyperphosphorylated form. On the other hand Munch- 
Petersen et al (1993) showed that purified TKl can shift 
reversibly between the high and low affinity forms by adding or 
removing ATP at 4°C. It is therefore unlikely that a protein 
kinase is involved, unless it can operate a 4'C and is a function 
of the TKl protein. However, a reversible autophosphorylation 
mechanism would also require a phosphatase activity and th.is is 
impossible within a 24 kDa protein. 
To explain the present results we propose the following 
model: Newly synthesized TKl protein in mammalian cells is 
modified by post-translational mechanisms in a way that prevents 
immidiate association to a tetramer. After binding of ATP a 
conformational change is induced that enable a tetramerization 
accompanied with a shift to higher affinity. The conformational 
change is promoted by increased thymidine and enzyme 
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concentration. Removal of ATP from the enzyme results in a change 
to a dimer form with low thymidine affinity. E.coli can not 
perform the post-translational modification and therefore the 
newly synthesized protein sub-units associates into a tight 
tetramer immidiately after translation. This tetramer can not 
dissociate into dimers at physiological conditions. 
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Fiaure lesends. 
Figure 1: 
The construction of the TKl-pET3a vector. The aminoacid-coding 
region of human TKl cDNA is PCR amplified by primers including 
restriction sites in the 5'end and inserted into the pET3a 
expression-vector using the restriction sites NdeI and BamHI. 
Figure 2: 
The sequencing-strategy to verify that the aminoacid-coding 
region in TKl-pET3a was identical to the published sequence of 
human TKl (Bradshaw & Deininger, 1984). The primers used are 
listed in MATERIALS. The small arrows indicate the primers and 
the long arrows show the bases sequenced by the primer. 
Figure 3: 
SDS-PAGE of purified recombinant TKl. Lane 1: Proteinmarker (97 
kDa, 66 kDa, 45 kDa, 31 kDa, 21 kDa, 14 kDa), lane 3; bacteria 
lysate, lane 4; wash from affinity chromatography, lane 6; 
purified recombinant TKl from affinity chromatography. 
Figure 4: 
The effect of ATP incubation on the thymidine substrate kinetics 
of purified recombinant TKl and TKl purified from lymphocytes. 
The open circles are the +ATP form of the enzyme and the filled 
circles are the -ATP form of the enzyme. (a) Hofstee plot of 
lymphocyte TKl and (b) Hill plots of the same data. (c) Hofstee 
plots of recombinant TKl and (d) Hill plots. 
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Figure 5: 
The molecular mass determined by G-200 superfine Sephadex. The 
column was calibrated by protein standards (12-20 KD). The +ATP 
forms are open circles and the -ATP form are filled cicles. The 
x-asis show fraction numbers collected from the column. (a) 
Elution of the +ATP and -ATP form of lymphocyte TKl. (b) Elution 
of the +ATP and -ATP form og recombinant TKl. (c) Protein 
standards are marked as filled squares with respect to molecular 
mass and elution fraction number. The molecular mass of the TKl 
enzymes are determined from elution fraction number. 
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Table 1. Comparison of the properties of lymphocyte TKl and 
recombinant TKl. 
Lymphocyte TKl Recombinant TKl 
Sub-unit molecular 
mass (kDa) 24 26 
Molecular +ATP 175 155 
mass (kDa) -ATP 75 155 
Thymidine Spec.act. 9,500 10,000 
nmol/min/mg 
"AZT +ATP 40% 46% 
as substrate -ATP 38% 
'ara-T +ATP 0% 0% 
as substrate -ATP 0% 
bATP +ATP 14* 31 
K, (PM) -ATP 140* 27 
bThymidine +ATP o-5-0.7 0.4 
K, (PM) -ATP 12-15 0.4 
"thy. Hill +ATP 1.2 1.5 
coefficient -ATP 0.7 1.4 
dTTP inhib. +ATP g-10* 1.5 
150 (PM) -ATP g-10. 1.5 
'The substrate analogs AZT and ara-T were determined in % of 
the activity with thymidine as substrate. 
bK, values for thymidine and ATP were calculated from Hofstee 
plots (v versus v/s). 
'The thymidine Hill coefficient were determined from Hill plots 
(log v/vmax- v versus log s). 
dISo for TTP is the inhibitor concentration at 50% inhibition. 
* Munch-Petersen et al (1995b) 
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